<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S022352342100372X</prism:url><dc:identifier>doi:10.1016/j.ejmech.2021.113523</dc:identifier><eid>1-s2.0-S022352342100372X</eid><prism:doi>10.1016/j.ejmech.2021.113523</prism:doi><pii>S0223-5234(21)00372-X</pii><dc:title>Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>02235234</prism:issn><prism:volume>221</prism:volume><prism:startingPage>113523</prism:startingpage><prism:pageRange>113523</prism:pagerange><articleNumber>113523</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2021-10-05</prism:coverdate><prism:coverDisplayDate>5 October 2021</prism:coverdisplaydate><prism:copyright>© 2021 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Ayati, Adileh</dc:creator><dc:creator>Moghimi, Setareh</dc:creator><dc:creator>Toolabi, Mahsa</dc:creator><dc:creator>Foroumadi, Alireza</dc:creator><dc:description>
                  Despite significant improvements of new treatment options, cancer continues to represent as one of the most common and fatal disease. The EGFR signaling pathway is considered as a significant approach in targeted therapy of cancers. Blocking the EGFR-driven pathway by inhibiting the intracellular tyrosine kinase domain of EGFR have shown considerable improvement in cancer therapy. In an effort to identify EGFR tyrosine kinase inhibitors (TKI), several small molecules especially pyrimidine containing derivatives have been designed by applying molecular simulation and evaluated the emergence of epigenetic mutation and resistance problems restricted the long-term effectiveness of such medication and explained the need for further investigations in this field. In recent years, the studies have been focused on genetic alterations on EGFR tyrosine kinase domain, which led to the design and synthesis of more selective and effective inhibitors. Herein, we give an overview of the importance and status of EGFR inhibitors in cancer therapy. In addition, we provide an update of the recent advances in design, discovery and development of novel pyrimidine containing compounds as promising selective EGFR TK inhibitors.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Anticancer</dcterms:subject><dcterms:subject>Targeted cancer therapy</dcterms:subject><dcterms:subject>EGFR tyrosine Kinase inhibitors TKI</dcterms:subject><dcterms:subject>Pyrimidine</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S022352342100372X" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S022352342100372X" rel="scidir"/></link></coredata><objects><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="599" size="56272">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="578" height="414" size="43513">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="667" height="972" size="137357">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="476" size="49310">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="984" size="105079">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="389" height="668" size="69240">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="ga1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="263" height="244" size="23223">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-ga1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="578" height="548" size="44204">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr12.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="387" height="313" size="22413">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="667" height="886" size="104272">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="389" height="884" size="87171">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="956" size="113616">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr11.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="667" height="591" size="59697">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="170" height="164" size="4882">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="157" size="6061">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="112" height="163" size="5167">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="199" height="163" size="7392">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="103" height="163" size="4040">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="95" height="163" size="4458">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="ga1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="176" height="163" size="13254">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-ga1.sml?httpAccept=%2A%2F%2A</object><object ref="gr12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="173" height="164" size="4516">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr12.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="203" height="164" size="4970">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="123" height="163" size="5211">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="72" height="164" size="4422">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="106" height="163" size="4359">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr11.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="185" height="164" size="5440">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="2653" size="432074">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2559" height="1835" size="322118">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2953" height="4302" size="1038928">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2568" height="2109" size="366259">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="4358" size="808149">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1722" height="2956" size="525921">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="ga1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1168" height="1085" size="200377">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-ga1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2559" height="2424" size="346569">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1713" height="1386" size="169142">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2953" height="3923" size="809599">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1722" height="3914" size="657353">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="4234" size="892295">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2953" height="2616" size="463094">https://api.elsevier.com/content/object/eid/1-s2.0-S022352342100372X-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object></objects><scopus-id>85105550794</scopus-id><scopus-eid>2-s2.0-85105550794</scopus-eid><pubmed-id>33992931</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85105550794" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20210504">2021-05-04</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20210504">2021-05-04</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20210513">2021-05-13</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20210513">2021-05-13</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2021-06-11T16:42:51</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S022352342100372X</xocs:eid>
      <xocs:pii-formatted>S0223-5234(21)00372-X</xocs:pii-formatted>
      <xocs:pii-unformatted>S022352342100372X</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2021.113523</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523421X00104</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210611">2021-06-11T22:33:10.854284Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20211005</xocs:date-search-begin>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1620143547">2021-05-04T15:52:27.555222Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor grantsponsorid highlightsabst orcid primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>221</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>221</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 221</xocs:vol-iss-suppl-text>
      <xocs:sort-order>5</xocs:sort-order>
      <xocs:first-fp>113523</xocs:first-fp>
      <xocs:article-number>113523</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>113523</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20211005</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>5 October 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-10-05</xocs:cover-date-start>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Review Papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>© 2021 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>PYRIMIDINEBASEDEGFRTKINHIBITORSINTARGETEDCANCERTHERAPY</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>AYATI</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>A</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Pyrimidine derivatives</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Amino pyrimidine derivatives</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Amino-pyrimidine derivatives</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2,4-Diamino substituted pyrimidine derivatives</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>4,6-Diamino substituted pyrimidine derivatives</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Miscellaneous derivatives</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Heterocyclic-fused pyrimidine derivatives</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Pyrrolo-pyrimidine derivatives</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Pyrazolo-pyrimidine containing compounds</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Pyrido-pyrimidine based compounds</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Pyrimido-pyrimidine derivatives</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Furo-pyrimidine based compounds</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Thieno-pyrimidine derivatives</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.2.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Thiopyrano-pyrimidine derivatives</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgement</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>AYATI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>699</xocs:ref-first-fp>
            <xocs:ref-last-lp>718</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>MILIK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>131</xocs:ref-first-fp>
            <xocs:ref-last-lp>151</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>AGHCHELI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>4</xocs:ref-first-fp>
            <xocs:ref-last-lp>11</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>SCHRANK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>224</xocs:ref-first-fp>
            <xocs:ref-last-lp>241</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>57</xocs:ref-first-fp>
            <xocs:ref-last-lp>66</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>AYATI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1929</xocs:ref-first-fp>
            <xocs:ref-last-lp>1952</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>DAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>55</xocs:ref-first-fp>
            <xocs:ref-last-lp>72</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>KYRIAKOPOULOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>99</xocs:ref-first-fp>
            <xocs:ref-last-lp>109</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>GORE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>148</xocs:ref-first-fp>
            <xocs:ref-last-lp>152</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>GUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>48</xocs:ref-first-fp>
            <xocs:ref-last-lp>49</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>BHATIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>112640</xocs:ref-article-number>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>22</xocs:ref-first-fp>
            <xocs:ref-last-lp>26</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>AGUSTONI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>15</xocs:ref-first-fp>
            <xocs:ref-last-lp>27</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>MOUNTZIOS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>6</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>CIARDIELLO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>9</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>AYATI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>103811</xocs:ref-article-number>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>TRAXLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>215</xocs:ref-first-fp>
            <xocs:ref-last-lp>234</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1070</xocs:ref-first-fp>
            <xocs:ref-last-lp>1074</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>PATEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>32</xocs:ref-first-fp>
            <xocs:ref-last-lp>47</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>51</xocs:ref-first-fp>
            <xocs:ref-last-lp>54</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>GRABE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>779</xocs:ref-first-fp>
            <xocs:ref-last-lp>782</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>GILBERT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>375</xocs:ref-first-fp>
            <xocs:ref-last-lp>386</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>KUMAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>29</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>FARAJI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2021</xocs:ref-pub-year>
            <xocs:ref-article-number>113228</xocs:ref-article-number>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1404</xocs:ref-first-fp>
            <xocs:ref-last-lp>1415</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>4290</xocs:ref-first-fp>
            <xocs:ref-last-lp>4300</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>GIRARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>2983</xocs:ref-first-fp>
            <xocs:ref-last-lp>2997</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>LU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>32</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>AN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>111709</xocs:ref-article-number>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>MCAULAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>10358</xocs:ref-first-fp>
            <xocs:ref-last-lp>10372</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>367</xocs:ref-first-fp>
            <xocs:ref-last-lp>380</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>GAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>4553</xocs:ref-first-fp>
            <xocs:ref-last-lp>4559</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>6135</xocs:ref-first-fp>
            <xocs:ref-last-lp>6145</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>12</xocs:ref-first-fp>
            <xocs:ref-last-lp>23</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>BASU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>2767</xocs:ref-first-fp>
            <xocs:ref-last-lp>2780</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>XIAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2673</xocs:ref-first-fp>
            <xocs:ref-last-lp>2680</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>ROMU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>4832</xocs:ref-first-fp>
            <xocs:ref-last-lp>4837</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>STOLPOVSKAYAA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1322</xocs:ref-first-fp>
            <xocs:ref-last-lp>1328</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>SINGH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>163</xocs:ref-first-fp>
            <xocs:ref-last-lp>170</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>CHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>4277</xocs:ref-first-fp>
            <xocs:ref-last-lp>4281</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>PATEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>393</xocs:ref-first-fp>
            <xocs:ref-last-lp>412</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>YAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>298</xocs:ref-first-fp>
            <xocs:ref-last-lp>306</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>FUSHENGZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1257</xocs:ref-first-fp>
            <xocs:ref-last-lp>1261</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>SONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>5505</xocs:ref-first-fp>
            <xocs:ref-last-lp>5512</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>YIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1988</xocs:ref-first-fp>
            <xocs:ref-last-lp>1997</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>SONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>329</xocs:ref-first-fp>
            <xocs:ref-last-lp>339</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>AI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>103408</xocs:ref-article-number>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>674</xocs:ref-first-fp>
            <xocs:ref-last-lp>697</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>SHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>115680</xocs:ref-article-number>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>LINGFENGCHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>510</xocs:ref-first-fp>
            <xocs:ref-last-lp>527</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>YE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1233</xocs:ref-first-fp>
            <xocs:ref-last-lp>1246</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1300</xocs:ref-first-fp>
            <xocs:ref-last-lp>1325</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>XIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>111943</xocs:ref-article-number>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>KHALED</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>103976</xocs:ref-article-number>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>ELKAMHAWY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>393</xocs:ref-first-fp>
            <xocs:ref-last-lp>405</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>ELKAMHAWY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>112</xocs:ref-first-fp>
            <xocs:ref-last-lp>118</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>HENGMIAOCHENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2005</xocs:ref-first-fp>
            <xocs:ref-last-lp>2024</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>KURUP</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>74</xocs:ref-first-fp>
            <xocs:ref-last-lp>84</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>FISCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2708</xocs:ref-first-fp>
            <xocs:ref-last-lp>2712</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>REIERSOLMOEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>102918</xocs:ref-article-number>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>ENGEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>5</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>GABER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>375</xocs:ref-first-fp>
            <xocs:ref-last-lp>395</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>ABDELGAWAD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>88</xocs:ref-first-fp>
            <xocs:ref-last-lp>96</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>MAHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>532</xocs:ref-first-fp>
            <xocs:ref-last-lp>546</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>SALEH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>12</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>11</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>JING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1784</xocs:ref-first-fp>
            <xocs:ref-last-lp>1796</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref68">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1107</xocs:ref-first-fp>
            <xocs:ref-last-lp>1117</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref69">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>112199</xocs:ref-first-fp>
            <xocs:ref-last-lp>112213</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref70">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>3619</xocs:ref-first-fp>
            <xocs:ref-last-lp>3633</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref71">
            <xocs:ref-normalized-surname>SHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>7302</xocs:ref-first-fp>
            <xocs:ref-last-lp>7308</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref72">
            <xocs:ref-normalized-surname>KHALIFA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>2635219</xocs:ref-article-number>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref73">
            <xocs:ref-normalized-surname>ELZAHABI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>546</xocs:ref-first-fp>
            <xocs:ref-last-lp>557</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref74">
            <xocs:ref-normalized-surname>ELSAYED</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>312</xocs:ref-first-fp>
            <xocs:ref-last-lp>323</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref75">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>221</xocs:ref-first-fp>
            <xocs:ref-last-lp>237</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref76">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>112061</xocs:ref-first-fp>
            <xocs:ref-last-lp>112076</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref77">
            <xocs:ref-normalized-surname>HAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>5609</xocs:ref-first-fp>
            <xocs:ref-last-lp>5622</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref78">
            <xocs:ref-normalized-surname>LU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1123</xocs:ref-first-fp>
            <xocs:ref-last-lp>1127</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref79">
            <xocs:ref-normalized-surname>HU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1281</xocs:ref-first-fp>
            <xocs:ref-last-lp>1287</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref80">
            <xocs:ref-normalized-surname>HAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>278</xocs:ref-first-fp>
            <xocs:ref-last-lp>299</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref81">
            <xocs:ref-normalized-surname>HOSSAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>330</xocs:ref-first-fp>
            <xocs:ref-last-lp>348</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref82">
            <xocs:ref-normalized-surname>COUMAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>4980</xocs:ref-first-fp>
            <xocs:ref-last-lp>4988</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref83">
            <xocs:ref-normalized-surname>PENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>3889</xocs:ref-first-fp>
            <xocs:ref-last-lp>3903</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref84">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>10108</xocs:ref-first-fp>
            <xocs:ref-last-lp>10123</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref85">
            <xocs:ref-normalized-surname>HANAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>534</xocs:ref-first-fp>
            <xocs:ref-last-lp>539</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref86">
            <xocs:ref-normalized-surname>KUMAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>3085</xocs:ref-first-fp>
            <xocs:ref-last-lp>3093</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref87">
            <xocs:ref-normalized-surname>BUGGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>255</xocs:ref-first-fp>
            <xocs:ref-last-lp>274</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref88">
            <xocs:ref-normalized-surname>MILIK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>316</xocs:ref-first-fp>
            <xocs:ref-last-lp>336</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref89">
            <xocs:ref-normalized-surname>ROMAGNOLI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1274</xocs:ref-first-fp>
            <xocs:ref-last-lp>1290</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref90">
            <xocs:ref-normalized-surname>TOOLABI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>111786</xocs:ref-article-number>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref91">
            <xocs:ref-normalized-surname>ABD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>21</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref92">
            <xocs:ref-normalized-surname>ELMETWALLY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>102944</xocs:ref-article-number>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref93">
            <xocs:ref-normalized-surname>MGHWARY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>838</xocs:ref-first-fp>
            <xocs:ref-last-lp>852</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref94">
            <xocs:ref-normalized-surname>XIAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>112511</xocs:ref-article-number>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref95">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>112388</xocs:ref-article-number>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref96">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>111809</xocs:ref-article-number>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref97">
            <xocs:ref-normalized-surname>XIAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>115669</xocs:ref-article-number>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>AYATIX2021X113523</xocs:refkey3>
         <xocs:refkey4ai>AYATIX2021X113523XA</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2023-05-13T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2023-05-13T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2021 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2021-05-01T18:10:45.657Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>NIMAD</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Institute for Medical Research Development</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100012155</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/130758</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(21)00372-X</xocs:pii-formatted>
         <xocs:pii-unformatted>S022352342100372X</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S022352342100372X</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2021.113523</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-06-11T22:33:10.854284Z</xocs:timestamp>
         <xocs:cover-date-start>2021-10-05</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/MAIN/application/pdf/5cd22f81b394515b82c72d5da6e6dc5c/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2070063</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>19</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S022352342100372X-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/PREVIEW/image/png/1d904ec73f182a013c85866ee7bdcf27/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>47225</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr6/DOWNSAMPLED/image/jpeg/47ae1789a06fc6ca601f1b56165f5ba9/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>56272</xocs:filesize>
               <xocs:pixel-height>599</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr9/DOWNSAMPLED/image/jpeg/83874d7e6515b1ad0e3d8498c8dc7305/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>43513</xocs:filesize>
               <xocs:pixel-height>414</xocs:pixel-height>
               <xocs:pixel-width>578</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr2/DOWNSAMPLED/image/jpeg/2836aede71df5af855caa1ee4901ed2f/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>137357</xocs:filesize>
               <xocs:pixel-height>972</xocs:pixel-height>
               <xocs:pixel-width>667</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr1/DOWNSAMPLED/image/jpeg/ee25813b2367995acf797710c036b8b7/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>49310</xocs:filesize>
               <xocs:pixel-height>476</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr7/DOWNSAMPLED/image/jpeg/450c21697ca9c0891a750f2515275420/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>105079</xocs:filesize>
               <xocs:pixel-height>984</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr3/DOWNSAMPLED/image/jpeg/cc670b5c1b44cd5a3c1913ee23c02818/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>69240</xocs:filesize>
               <xocs:pixel-height>668</xocs:pixel-height>
               <xocs:pixel-width>389</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-ga1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/ga1/DOWNSAMPLED/image/jpeg/6e1b64d7652b0405e5e89cdf08a2ecc6/ga1.jpg</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23223</xocs:filesize>
               <xocs:pixel-height>244</xocs:pixel-height>
               <xocs:pixel-width>263</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr12/DOWNSAMPLED/image/jpeg/44bd58b4cbd3825b7946617650645bd9/gr12.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>44204</xocs:filesize>
               <xocs:pixel-height>548</xocs:pixel-height>
               <xocs:pixel-width>578</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr4/DOWNSAMPLED/image/jpeg/d16fe0bcbd456a496c64c75b842cbd5e/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>22413</xocs:filesize>
               <xocs:pixel-height>313</xocs:pixel-height>
               <xocs:pixel-width>387</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr10/DOWNSAMPLED/image/jpeg/a3c7aaab33a05b46200f6554201f41d7/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>104272</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>667</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr8/DOWNSAMPLED/image/jpeg/9a65e0847605e83fc999a2365af55260/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>87171</xocs:filesize>
               <xocs:pixel-height>884</xocs:pixel-height>
               <xocs:pixel-width>389</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr11/DOWNSAMPLED/image/jpeg/7e54b6c7bcbe63af6337e2de4036bad9/gr11.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>113616</xocs:filesize>
               <xocs:pixel-height>956</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr5/DOWNSAMPLED/image/jpeg/9d45ed7dbc629649a1739282d4f144ac/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>59697</xocs:filesize>
               <xocs:pixel-height>591</xocs:pixel-height>
               <xocs:pixel-width>667</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr6/THUMBNAIL/image/gif/71600f3dab3b1eb103c0d5cb6e2a44cd/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4882</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>170</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr9/THUMBNAIL/image/gif/142b9ddfcf2131af69ff2a3c1d17c106/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6061</xocs:filesize>
               <xocs:pixel-height>157</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr2/THUMBNAIL/image/gif/0a6c7b05a2accf8567fd1c994a86582c/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5167</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>112</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr1/THUMBNAIL/image/gif/87335ca0ac0c57df32697dae6bf1546c/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7392</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>199</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr7/THUMBNAIL/image/gif/07edc6fd618c21ff2b4ae55a2f7f64bf/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4040</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>103</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr3/THUMBNAIL/image/gif/9473c2efeae49b25144c1087a7cffdc9/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4458</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>95</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-ga1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/ga1/THUMBNAIL/image/gif/075c367bba6959402a16f938077f0c3a/ga1.sml</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13254</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>176</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr12/THUMBNAIL/image/gif/eb37ea813912fab5e5d0910464a9237b/gr12.sml</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4516</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>173</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr4/THUMBNAIL/image/gif/965c776825307a6d01d5543dcf6ee574/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4970</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>203</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr10/THUMBNAIL/image/gif/157bc0044dbf08da3804fda4b8889729/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5211</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>123</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr8/THUMBNAIL/image/gif/a3e24222a1db42fdee676ebae28c0b3b/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4422</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>72</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr11/THUMBNAIL/image/gif/168c719a8032593059b1b0ab0519af55/gr11.sml</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4359</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>106</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr5/THUMBNAIL/image/gif/230355dc4d797e95e8688539ff4b9566/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5440</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>185</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr6/HIGHRES/image/jpeg/081db6eb61c9bcb004d008826d884f13/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>432074</xocs:filesize>
               <xocs:pixel-height>2653</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr9/HIGHRES/image/jpeg/4c41cd3c1b1dbdafd38b9df8ebfe340b/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>322118</xocs:filesize>
               <xocs:pixel-height>1835</xocs:pixel-height>
               <xocs:pixel-width>2559</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr2/HIGHRES/image/jpeg/4e519d3ae93c566ad460146b1432a31b/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1038928</xocs:filesize>
               <xocs:pixel-height>4302</xocs:pixel-height>
               <xocs:pixel-width>2953</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr1/HIGHRES/image/jpeg/fcc8242979073948be09bc24c6c4b745/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>366259</xocs:filesize>
               <xocs:pixel-height>2109</xocs:pixel-height>
               <xocs:pixel-width>2568</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr7/HIGHRES/image/jpeg/ef4605e2c42cee6552ef299bedb5f6a4/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>808149</xocs:filesize>
               <xocs:pixel-height>4358</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr3/HIGHRES/image/jpeg/8a6d0adaa78137948cfb289bf47e7587/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>525921</xocs:filesize>
               <xocs:pixel-height>2956</xocs:pixel-height>
               <xocs:pixel-width>1722</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-ga1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/ga1/HIGHRES/image/jpeg/6603839d4b0b5b480387e7b719cca91e/ga1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>200377</xocs:filesize>
               <xocs:pixel-height>1085</xocs:pixel-height>
               <xocs:pixel-width>1168</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr12/HIGHRES/image/jpeg/ba2ff00e16e4bcacf0e5cd8546123a77/gr12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr12</xocs:file-basename>
               <xocs:filename>gr12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>346569</xocs:filesize>
               <xocs:pixel-height>2424</xocs:pixel-height>
               <xocs:pixel-width>2559</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr4/HIGHRES/image/jpeg/17fc8fe51af7281d4c5db416f01fd365/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>169142</xocs:filesize>
               <xocs:pixel-height>1386</xocs:pixel-height>
               <xocs:pixel-width>1713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr10/HIGHRES/image/jpeg/cc11a83b7c60604e8201ebfb50a30389/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>809599</xocs:filesize>
               <xocs:pixel-height>3923</xocs:pixel-height>
               <xocs:pixel-width>2953</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr8/HIGHRES/image/jpeg/e6485414de35484168a0afe970164a8f/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>657353</xocs:filesize>
               <xocs:pixel-height>3914</xocs:pixel-height>
               <xocs:pixel-width>1722</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr11/HIGHRES/image/jpeg/4af97f47dc2d17c06401bfddaebdb0a9/gr11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>892295</xocs:filesize>
               <xocs:pixel-height>4234</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S022352342100372X-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S022352342100372X/gr5/HIGHRES/image/jpeg/dd0a36199ac42d0b053238529ac0b52a/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>463094</xocs:filesize>
               <xocs:pixel-height>2616</xocs:pixel-height>
               <xocs:pixel-width>2953</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="rev" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>113523</aid>
            <ce:article-number>113523</ce:article-number>
            <ce:pii>S0223-5234(21)00372-X</ce:pii>
            <ce:doi>10.1016/j.ejmech.2021.113523</ce:doi>
            <ce:copyright type="full-transfer" year="2021">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Structures of pyrimidine containing drugs.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0015" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S022352342100372X/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Structures of 2-amino-pyrimidine derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S022352342100372X/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Structures of 2,4-diamino substituted pyrimidine derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S022352342100372X/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Structures of 4,6-diamino substituted pyrimidine derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S022352342100372X/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Structures of other derivatives of pyrimidine containing compounds.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S022352342100372X/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Structures of pyrrolo-pyrimidine containing derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S022352342100372X/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Structure of pyrazolo-pyrimidine containing compounds.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S022352342100372X/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Structures of pyrido-pyrimidine based derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S022352342100372X/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig. 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Structures of pyrimido-pyrimidine containing derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Fig. 9</ce:alt-text>
               <ce:link locator="gr9" xlink:href="pii:S022352342100372X/gr9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig. 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Structure of furo-pyrimidine based compounds.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Fig. 10</ce:alt-text>
               <ce:link locator="gr10" xlink:href="pii:S022352342100372X/gr10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig11">
               <ce:label>Fig. 11</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Structures of thieno-pyrimidine containing derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Fig. 11</ce:alt-text>
               <ce:link locator="gr11" xlink:href="pii:S022352342100372X/gr11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig12">
               <ce:label>Fig. 12</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0065" view="all">Structures of thiopyrano-pyrimidine derivatives.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Fig. 12</ce:alt-text>
               <ce:link locator="gr12" xlink:href="pii:S022352342100372X/gr12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Review article</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S022352342100372X-5e9cef670852e335310a617af6df4000">
                  <ce:given-name>Adileh</ce:given-name>
                  <ce:surname>Ayati</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S022352342100372X-411b683a789bd40dd1591e526d879ff6">
                  <ce:given-name>Setareh</ce:given-name>
                  <ce:surname>Moghimi</ce:surname>
                  <ce:cross-ref id="crosref0015" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S022352342100372X-c5ce1cb37484c67ac9daabd408069b19">
                  <ce:given-name>Mahsa</ce:given-name>
                  <ce:surname>Toolabi</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0030" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au4" orcid="0000-0003-2416-5611" author-id="S022352342100372X-bed3b5978570922b29348f2acf1303f6">
                  <ce:given-name>Alireza</ce:given-name>
                  <ce:surname>Foroumadi</ce:surname>
                  <ce:cross-ref id="crosref0035" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0040" refid="aff4">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0045" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S022352342100372X-928b8920e99bafbd9aaade477ae46b36">
                  <ce:label>a</ce:label>
                  <ce:textfn>Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Drug Design and Development Research Center</sa:organization>
                     <sa:organization>The Institute of Pharmaceutical Sciences (TIPS)</sa:organization>
                     <sa:organization>Tehran University of Medical Sciences</sa:organization>
                     <sa:city>Tehran</sa:city>
                     <sa:country>Iran</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S022352342100372X-4db25bc4fdd13d291e91ee0b269252fa">
                  <ce:label>b</ce:label>
                  <ce:textfn>Department of Medicinal Chemistry, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Medicinal Chemistry</sa:organization>
                     <sa:organization>School of Pharmacy</sa:organization>
                     <sa:organization>Ahvaz Jundishapur University of Medical Sciences</sa:organization>
                     <sa:city>Ahvaz</sa:city>
                     <sa:country>Iran</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Department of Medicinal Chemistry, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S022352342100372X-fdf4301135554e66523dedf2b941c541">
                  <ce:label>c</ce:label>
                  <ce:textfn>Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Toxicology Research Center</sa:organization>
                     <sa:organization>Medical Basic Sciences Research Institute</sa:organization>
                     <sa:organization>Ahvaz Jundishapur University of Medical Sciences</sa:organization>
                     <sa:city>Ahvaz</sa:city>
                     <sa:country>Iran</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff4" affiliation-id="S022352342100372X-ad4c0d897bd72207e1a25cc332fca588">
                  <ce:label>d</ce:label>
                  <ce:textfn>Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Medicinal Chemistry</sa:organization>
                     <sa:organization>Faculty of Pharmacy</sa:organization>
                     <sa:organization>Tehran University of Medical Sciences</sa:organization>
                     <sa:city>Tehran</sa:city>
                     <sa:country>Iran</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0025">Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author. Department of Medicinal Chemistry, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</ce:text>
                  <sa:affiliation>
                     <sa:organization>Department of Medicinal Chemistry</sa:organization>
                     <sa:organization>School of Pharmacy</sa:organization>
                     <sa:organization>Ahvaz Jundishapur University of Medical Sciences</sa:organization>
                     <sa:city>Ahvaz</sa:city>
                     <sa:country>Iran</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author. Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.</ce:text>
                  <sa:affiliation>
                     <sa:organization>Drug Design and Development Research Center</sa:organization>
                     <sa:organization>The Institute of Pharmaceutical Sciences (TIPS)</sa:organization>
                     <sa:organization>Tehran University of Medical Sciences</sa:organization>
                     <sa:city>Tehran</sa:city>
                     <sa:country>Iran</sa:country>
                  </sa:affiliation>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="12" month="12" year="2020"/></ce:date-received>
            <ce:date-revised day="25" month="3" year="2021"/></ce:date-revised>
            <ce:date-accepted day="22" month="4" year="2021"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Despite significant improvements of new treatment options, cancer continues to represent as one of the most common and fatal disease. The EGFR signaling pathway is considered as a significant approach in targeted therapy of cancers. Blocking the EGFR-driven pathway by inhibiting the intracellular tyrosine kinase domain of EGFR have shown considerable improvement in cancer therapy. In an effort to identify EGFR tyrosine kinase inhibitors (TKI), several small molecules especially pyrimidine containing derivatives have been designed by applying molecular simulation and evaluated the emergence of epigenetic mutation and resistance problems restricted the long-term effectiveness of such medication and explained the need for further investigations in this field. In recent years, the studies have been focused on genetic alterations on EGFR tyrosine kinase domain, which led to the design and synthesis of more selective and effective inhibitors. Herein, we give an overview of the importance and status of EGFR inhibitors in cancer therapy. In addition, we provide an update of the recent advances in design, discovery and development of novel pyrimidine containing compounds as promising selective EGFR TK inhibitors.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="ga1" xlink:href="pii:S022352342100372X/ga1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Anticancer</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Targeted cancer therapy</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>EGFR tyrosine Kinase inhibitors TKI</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Pyrimidine</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0025" view="all">Cancer is a life threatening disease representing as the second leading cause of death in the world [<ce:cross-ref id="crosref0050" refid="bib1">1</ce:cross-ref>]. The growing trend of cancers explains an urgent need for research, prevention, and treatment aspects [<ce:cross-ref id="crosref0055" refid="bib2">2</ce:cross-ref>]. Despite the significant advances in the management of cancer, the severe side effects and emergence of acquired drug resistance [<ce:cross-ref id="crosref0060" refid="bib3">3</ce:cross-ref>]. In addition, most of the known chemotherapeutic drugs suffered from low efficacy and severe toxicity mainly due to the lack of selectivity. Targeted cancer therapies are considered as one of the most promising ways of resolving this problem referring to a new generation of cancer drugs which were designed to interfere with a specific target protein or enzyme [<ce:cross-ref id="crosref0065" refid="bib4">4</ce:cross-ref>,<ce:cross-ref id="crosref0070" refid="bib5">5</ce:cross-ref>]. This revolutionary treatment approach has found its position by reducing the severity of chemotherapy side effects and have enabled us to personalize the modified treatment regimens for each patient [<ce:cross-ref id="crosref0075" refid="bib6">6</ce:cross-ref>].</ce:para>
                  <ce:para id="p0030" view="all">The epidermal growth factor receptor (EGFR) is a family of four related transmembrane tyrosine kinase receptors [<ce:cross-ref id="crosref0080" refid="bib7">7</ce:cross-ref>]. EGFR family play a critical role in mediating growth factor signaling in cells by activating a number of important cellular processes including cell division, growth, differentiation, metabolism, adhesion, motility and death [<ce:cross-ref id="crosref0085" refid="bib8">8</ce:cross-ref>]. The inactive monomer receptors have been dimerized and subsequently became activated by the ligand binding to the extracellular domain. The EGFR/ligand binding (including EGF and transforming growth factor (TGF)) results in the phosphorylation of intracellular tyrosine kinase domain, initiation of downstream signaling pathways and ends up in the cell proliferation and inhibition of apoptosis [<ce:cross-ref id="crosref0090" refid="bib9">9</ce:cross-ref>]. Pathologically, EGFR signaling overexpression extensively facilitates tumor progression and leads to promote proliferation and apoptosis inhibition [<ce:cross-ref id="crosref0095" refid="bib10">10</ce:cross-ref>]. EGFR dysregulation is observed in a vast number of tumors such as non-small-cell lung cancer (NSCLC), colon cancer, head-and-neck cancer, breast and ovarian cancer. Hence, EGFR has been recognized as the strong and rational target in the treatment of cancers [<ce:cross-ref id="crosref0100" refid="bib11">11</ce:cross-ref>].</ce:para>
                  <ce:para id="p0035" view="all">As EGFR is known as the key player in the regulation and activation of important cellular processes, the development of molecular agents targeting EGFR signaling pathway is a well-known strategy for the design of promising anti-cancer drugs. Selective anti-EGFR agents include the monoclonal antibody and small molecule kinase inhibitors [<ce:cross-ref id="crosref0105" refid="bib12">12</ce:cross-ref>]. Anti-EGFR monoclonal antibodies, the first highly selective EGFR molecular target, bind to the extracellular domain of EGFR on the surface of tumor cells and compete for receptor binding by occluding the ligand-binding region, and block ligand-induced EGFR tyrosine kinase activation [<ce:cross-refs id="crosrefs0010" refid="bib13 bib14 bib15">13–15</ce:cross-refs>]. The small molecule tyrosine kinase inhibitors (TKIs) bind competitively and reversibly to the ATP-binding site of the intracellular EGFR tyrosine kinase (TK) domain and inhibit EGFR auto-phosphorylation and downstream signaling pathways [<ce:cross-ref id="crosref0110" refid="bib16">16</ce:cross-ref>].</ce:para>
                  <ce:para id="p0040" view="all">Over the last decades, several small molecules especially pyrimidine containing compounds were designed by the molecular simulation and evaluated as intracellular inhibitors of EGFR tyrosine kinase (TK) domain [<ce:cross-ref id="crosref0115" refid="bib17">17</ce:cross-ref>]. Clinical data have shown the significant influence of pyrimidine derivatives as EGFR TK inhibitors in several successful FDA-approved drugs [<ce:cross-ref id="crosref0120" refid="bib18">18</ce:cross-ref>]. However, the effectiveness of such therapies were mainly restricted by rapid epigenetic mutations in kinase domain of EGFR and the subsequent resistance to the drugs [<ce:cross-ref id="crosref0125" refid="bib19">19</ce:cross-ref>]. Strong efforts were directed to the identification of gene alterations in kinase domain of EFGR. These tries led to the design of more effective inhibitors that selectively address the mutations [<ce:cross-ref id="crosref0130" refid="bib20">20</ce:cross-ref>]. In this regard, a large number of pyrimidine containing derivatives were evaluated with the capability of inhibiting specific mutation in EGFR tyrosine kinase domain [<ce:cross-ref id="crosref0135" refid="bib21">21</ce:cross-ref>]. Different strategies were also used for the optimization and improvement of selective pyrimidine-based inhibitors. Presently, various classes of selective pyrimidine containing molecules have been presented to the clinical application with increased residence time to EGFR [<ce:cross-ref id="crosref0140" refid="bib22">22</ce:cross-ref>]. This review provides an overview of targeting EGFR kinase domain as a novel approach in cancer targeted therapy by summarizing the latest findings on the discovery and the development of pyrimidine containing compounds as small molecule EGFR TK inhibitors. Further strategies for the design and the development of selective pyrimidine-based inhibitors would be explained in details.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Pyrimidine derivatives</ce:section-title>
                  <ce:para id="p0045" view="all">Pyrimidines, an attractive class of heterocyclic compounds, are known by the wide range of biological activities [<ce:cross-ref id="crosref0145" refid="bib23">23</ce:cross-ref>]. Pyrimidine containing derivatives have gained a great deal of attention, especially for their considerable antiproliferative activity [<ce:cross-ref id="crosref0150" refid="bib24">24</ce:cross-ref>]. Considering the important role of EGFR TK inhibitors, a multitude of pyrimidine-based analogs were synthesized and evaluated for their abilities in targeting various protein kinase enzymes, including EGFR tyrosine kinase. These kinds of inhibitors were successfully designed to target different mutations in tyrosine kinase domain of EGFR and used as the effective treatment agents against several cancers with EGFR over-activation such as non-small cell lung cancer (NSCLC) [<ce:cross-ref id="crosref0155" refid="bib25">25</ce:cross-ref>]. WZ40028 (<ce:cross-ref id="crosref0160" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>) is the first reported pyrimidine-based compound, belongs to the third-generation EGFR TK inhibitor, with promising inhibitory activity against mutant EGFR<ce:sup loc="post">T790M</ce:sup> [<ce:cross-ref id="crosref0165" refid="bib26">26</ce:cross-ref>]. Osimertinib (AZD9291) (<ce:cross-ref id="crosref0170" refid="fig1">Fig. 1</ce:cross-ref>) is the first FDA-approved pyrimidine containing drug with remarkable clinical efficacy against NSCLC [<ce:cross-ref id="crosref0175" refid="bib27">27</ce:cross-ref>]. In addition, rociletinib (CO1686) and olmutinib (HM61713) (<ce:cross-ref id="crosref0180" refid="fig1">Fig. 1</ce:cross-ref>) were developed as other examples from the third-generation EGFR TK inhibitors which take advantages of increased residence time to EGFR by alkylating Cys797 [<ce:cross-ref id="crosref0185" refid="bib28">28</ce:cross-ref>]. Despite the rapidly developed resistances which led to the decreased long-term effectiveness of such inhibitors, studies are still ongoing to find more efficient pyrimidine containing EGFR inhibitors. In this review, the pyrimidine containing inhibitors are investigated and categorized as 2-anilino-pyrimidine, 2,4-diarylamino-pyrimidine, 4,6-diaryl-pyrimidine and heterocyclic fused pyrimidine derivatives including pyrrolo-pyrimidine, pyrazolo-pyrimidine, pyrido-pyrimidine, pyrimido-pyrimidine, furo-pyrimidine, thieno-pyrimidine and thiopyrano-pyrimidine containing compounds.</ce:para>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Amino pyrimidine derivatives</ce:section-title>
                     <ce:section id="sec2.1.1" view="all">
                        <ce:label>2.1.1</ce:label>
                        <ce:section-title id="sectitle0045">2-Amino-pyrimidine derivatives</ce:section-title>
                        <ce:para id="p0050" view="all">A novel series of sulfoxide containing AZD9291 derivatives were evaluated against a panel of three human cancer cell lines (including H292 (harbors wild-type EGFR), PC9 (harbors mutant EGFR<ce:sup loc="post">L858R</ce:sup>), H1975 (harbors double mutant EGFR<ce:sup loc="post">T790M/L858R</ce:sup>). In the present study, AZD9291 was modified by adding a sulfoxide side chain at the C-4 position of the aniline moiety to reduce the side effects. Based on the results, the chiral compound <ce:bold>1</ce:bold> (<ce:cross-ref id="crosref0190" refid="fig2">Fig. 2</ce:cross-ref>
                           <ce:float-anchor refid="fig2"/></ce:float-anchor>) exhibited excellent inhibitory activity and selectivity against H292 (harboring EGFR<ce:sup loc="post">WT</ce:sup>, IC<ce:inf loc="post">50</ce:inf> = 0.013 μM) and PC9 (harboring mutant EGFR<ce:sup loc="post">L858R</ce:sup>, IC<ce:inf loc="post">50</ce:inf> = 0.017 μM) cancer cells with the best inhibition against double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> kinase with the IC<ce:inf loc="post">50</ce:inf> value of 5 nM. Further analysis confirmed that compound <ce:bold>1</ce:bold> induced cell apoptosis and reduced phosphorylation of EGFR and AKT in a dose-dependent manner with significant reduction of the tumor volume (TGI: 94.30%). Molecular modeling study confirmed the U-shaped configuration of compound <ce:bold>1</ce:bold> with covalent bond of acrylamide residue in the ATP binding site of EGFR. In addition, S=O functional group composed further binding to the active site of mutant EGFR<ce:sup loc="post">T790M</ce:sup> [<ce:cross-ref id="crosref0195" refid="bib29">29</ce:cross-ref>]. A series of 2-amino-pyrimidine-based compounds containing different heterocyclic warheads were synthesized and examined against a panel of protein kinases. The focus of the study was the design and synthesis of novel covalent inhibitors different from acrylamide-based inhibitors. The structural modifications on the acrylamide warhead led to the identification of the more selective inhibitors with improved <ce:italic>in vitro</ce:italic> pharmacokinetic profile relative to the former synthesized acrylamide-based inhibitors. Based on the enzymatic assay results, compound <ce:bold>2c</ce:bold> was highly potent against Janus kinase 3 (JAK3) with the IC<ce:inf loc="post">50</ce:inf> of 0.06 μM, while compounds <ce:bold>2a</ce:bold> and <ce:bold>2b</ce:bold> (<ce:cross-ref id="crosref0200" refid="fig2">Fig. 2</ce:cross-ref>) had promising results against mutant EGFR<ce:sup loc="post">T790M</ce:sup> with IC<ce:inf loc="post">50s</ce:inf> = 0.18 and 0.22 μM, respectively [<ce:cross-ref id="crosref0205" refid="bib30">30</ce:cross-ref>]. Three series of pyrimidine containing compounds were synthesized as AZD9291 derivatives and evaluated against H1975, A549 and HepG2 cell lines. The title compounds were designed with different substituents at the C-5 or C-6 positions of the pyrimidine ring with various moieties substituted at the end of the acrylamide side chain. The cyano containing compound <ce:bold>3</ce:bold> (<ce:cross-ref id="crosref0210" refid="fig2">Fig. 2</ce:cross-ref>) demonstrated potent inhibitory activity with the IC<ce:inf loc="post">50</ce:inf> values less than 0.4 μM which were better than AZD9291 against A549 and HepG2 cells. This compound also showed excellent enzymatic activity for double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> with IC<ce:inf loc="post">50</ce:inf> = 8 μM, and selectivity over EGFR<ce:sup loc="post">WT</ce:sup> with IC<ce:inf loc="post">50</ce:inf> = 191.3 μM. Moreover, compound <ce:bold>3</ce:bold> inhibited the proliferation of H1975 cells at G2/M phase and induced apoptosis at the concentration of 0.25 μM. The binding mode of compound <ce:bold>3</ce:bold> showed three hydrogen bonds between Met793 and Cys797 of EGFR protein with the hydrogen atom of the imine and the nitrogen atom in the 1-position of the pyrimidine ring and the oxygen atoms in the acrylamide side chains [<ce:cross-ref id="crosref0215" refid="bib31">31</ce:cross-ref>]. A series of <ce:italic>N</ce:italic>-oxidized metabolite-based and fluorinated osimertinib derivatives were designed to prevent <ce:italic>N</ce:italic>-methylation metabolic reactions in <ce:italic>N,N,N</ce:italic>-trimethylethylenediamine side chain and the <ce:italic>N</ce:italic>-methylindole motif of osimertinib. The best <ce:italic>in vitro</ce:italic> anti-proliferative and kinase inhibitory activity were observed by the fluorinated compound <ce:bold>4b</ce:bold> (<ce:cross-ref id="crosref0220" refid="fig2">Fig. 2</ce:cross-ref>) against double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> (IC<ce:inf loc="post">50</ce:inf> = 4.9 nM) with good selectivity over wild-type EGFR (166.3 nM, respectively). The <ce:italic>N</ce:italic>-oxide metabolite of osimertinib, compound <ce:bold>4a</ce:bold> (<ce:cross-ref id="crosref0225" refid="fig2">Fig. 2</ce:cross-ref>), showed better kinase selectivity (kinase selectivity = 49.9 wild-type EGFR over double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup>) and the comparable <ce:italic>in vivo</ce:italic> antitumor efficacy compared to osimertinib in NCI-H1975 xenografts (harboring mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup>) [<ce:cross-ref id="crosref0230" refid="bib32">32</ce:cross-ref>]. 18 new osimertinib analogs were synthesized in order to prevent metabolic reactions and <ce:italic>N</ce:italic>-demethylation. In this regard, the target compounds were designed through changing the indole motif (replacing with other hetrocycles such as benzo-isoxazole, pyrrolo-pyridine and thieno-pyrazole), alkoxy group (replacing with methoxy and difluoromethoxy) and cyclization of linear structure of <ce:italic>N,N,N</ce:italic>-trimethylethylenediamine in tail chains. The <ce:italic>N</ce:italic>-dimethyl metabolites of osimertinib were synthesized and screened by <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> analysis. The pyrrolo-pyridine derivative <ce:bold>5</ce:bold> (<ce:cross-ref id="crosref0235" refid="fig2">Fig. 2</ce:cross-ref>) and its main human hepatocyte metabolites, showed over 30 fold selectivity (against mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> over EGFR<ce:sup loc="post">WT</ce:sup>) in both enzymatic and cellular assays. Also, compound <ce:bold>5</ce:bold> demonstrated significant antitumor efficacy and good tolerability in NCI-H1975, PC-9 and HCC827 xenografts mouse models, making it a potential candidate for human clinical test [<ce:cross-ref id="crosref0240" refid="bib33">33</ce:cross-ref>]. A number of 2-amino-pyrimidines were designed based on the modeling binding mode of AZD9291 with mutant EGFR<ce:sup loc="post">T790M</ce:sup> kinase. The potency and physical properties of synthesized inhibitors were evaluated by the attachment of amine side chains. These modifications led to reduced cardiotoxicity of synthesized derivatives compared to AZD9291. The obtained results indicated that the expanded indole ring derivative <ce:bold>6</ce:bold> with, 5,6-dihydro-4<ce:italic>H</ce:italic>-pyrrolo-[3,2,1-<ce:italic>ij</ce:italic>] quinolone motif (<ce:cross-ref id="crosref0245" refid="fig2">Fig. 2</ce:cross-ref>) was the most promising inhibitor, which potently inhibited the enzymatic activity of double mutant EGFR<ce:sup loc="post">T790M/L858R</ce:sup> with the IC<ce:inf loc="post">50</ce:inf> = 2.9 nM and the proliferation of H1975 cancer cells with the IC<ce:inf loc="post">50</ce:inf> = 102.6 nM. This compound significantly inhibited tumor growth in the EGFR<ce:sup loc="post">T790M/L858R</ce:sup>-driven human NSCLC xenograft mouse model by dosing 20 mg/kg/day. The good pharmacokinetic properties with oral bioavailability of 52.4% and less cardiotoxicity than AZD9291 was observed [<ce:cross-ref id="crosref0250" refid="bib34">34</ce:cross-ref>]. Design, synthesis and EGFR inhibitory evaluation of 2-anilino-pyrimidine derivatives were reported by Basu et al. as the covalent reversible WZ4002 analogs. The synthesized compounds were designed based on the modifications at <ce:italic>α</ce:italic>- and <ce:italic>β</ce:italic>-carbon of acrylamide chain (Michael acceptor) with various aromatic and aliphatic substituents. Among the synthesized derivatives, 2-cyano-acrylamide scaffolds exhibited strong activity and selectivity against mutants EGFR<ce:sup loc="post">L858R</ce:sup> and EGFR<ce:sup loc="post">L858R/T790M</ce:sup> with IC<ce:inf loc="post">50</ce:inf> less than 2.5 μM. Compound <ce:bold>7</ce:bold> containing polar motif (4-pyridyl group) (<ce:cross-ref id="crosref0255" refid="fig2">Fig. 2</ce:cross-ref>) was found to be the most potent inhibitor with IC<ce:inf loc="post">50</ce:inf> = 37 nM against double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> [<ce:cross-ref id="crosref0260" refid="bib35">35</ce:cross-ref>]. The structure-based drug design led to the discovery and development of 5-(methylthio)pyrimidines, by optimizing the structure of WZ4002. Methylthio group was chosen for its hydrophobic, bulky properties and unique electrical character, which led to the better hydrophobic interaction with the residue of Met790 in mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup>. The synthesized derivatives showed strong enzymatic and cellular inhibitory activities compared to WZ4002 and CO1686 as the standards. Fluorinated derivatives <ce:bold>8c</ce:bold> and <ce:bold>8d</ce:bold> (<ce:cross-ref id="crosref0265" refid="fig2">Fig. 2</ce:cross-ref>) had the highest activity and selectivity against H1975 cells (harbors T790M/L858R mutation) with IC<ce:inf loc="post">50</ce:inf> values of 20 and 88 nM, respectively, while compounds <ce:bold>8a</ce:bold> and 8<ce:bold>b</ce:bold> (<ce:cross-ref id="crosref0270" refid="fig2">Fig. 2</ce:cross-ref>) showed this trend in enzymatic assay against EGFR<ce:sup loc="post">L858R/T790M</ce:sup> with IC<ce:inf loc="post">50</ce:inf> values of 0.4 and 0.7 nM, respectively. Further, the EGFR kinase inhibitory and anti-proliferative activities of these derivatives were confirmed by western blot analysis in H1975 and A431 cells [<ce:cross-ref id="crosref0275" refid="bib36">36</ce:cross-ref>]. Thirty-two, 2-anilino-pyrimidines were synthesized as another WZ4002 analog and evaluated against six different EGFR kinases (including EGFR<ce:sup loc="post">WT</ce:sup>, EGFR<ce:sup loc="post">d746–750</ce:sup>, EGFR<ce:sup loc="post">T790M</ce:sup>, EGFR<ce:sup loc="post">T790M/L858R</ce:sup>, EGFR<ce:sup loc="post">C797S</ce:sup> and EGFR<ce:sup loc="post">T790M/L858R/C797S</ce:sup>). To overcome the resistance problems of both T790M and C797S mutations, compounds with electrophilic and non-electrophilic groups with different hydrophilic and lipophilic characteristics were also synthesized. Compound <ce:bold>9a</ce:bold> (<ce:cross-ref id="crosref0280" refid="fig2">Fig. 2</ce:cross-ref>) exhibited complete inhibition at 10 μM concentration against all the six kinases while compounds <ce:bold>9b-e</ce:bold> (<ce:cross-ref id="crosref0285" refid="fig2">Fig. 2</ce:cross-ref>) exhibited complete inhibition at 10 μM against the triple mutant EGFR<ce:sup loc="post">T790M/C797S/L858R</ce:sup>kinase, and nearly complete inhibition at 1 μM. Furthermore, the benzyloxy and hydroxy containing compounds <ce:bold>9b-f</ce:bold> were found to be the most potent toward all five tested cell lines (including PC9, PC9-GR, H460, Ba/F3-WT and Ba/F3-T3151 cancer cells) with IC<ce:inf loc="post">50s</ce:inf> less than 4.5 μM [<ce:cross-ref id="crosref0290" refid="bib37">37</ce:cross-ref>]. Inspired by the promising EGFR inhibitory activity of 2-anilino pyrimidine derivatives, the synthesis and biological evaluation of a series of 2-anilino-pyrimidin-2-yl thioureas and 2-anilino-(1,3-thiazol-2-yl)-pyrimidin-2-amines were reported. Based on the results, thiourea derivatives <ce:bold>10a</ce:bold> and <ce:bold>10b</ce:bold> (<ce:cross-ref id="crosref0295" refid="fig2">Fig. 2</ce:cross-ref>) showed promising inhibitory effects toward several protein kinases, especially against single and double mutant EGFR tyrosine kinases (EGFR<ce:sup loc="post">L858R</ce:sup>, EGFR<ce:sup loc="post">T790M/L858R</ce:sup>) with 62–89% inhibition in enzymatic assays [<ce:cross-ref id="crosref0300" refid="bib38">38</ce:cross-ref>]. Indole-pyrimidine derivatives were designed using <ce:italic>in silico</ce:italic> study and evaluated as non-covalent reversible inhibitors of mutant EGFR. The focus was laid on the hydrophobic interaction with mutant EGFR by incorporation of different substituted aryl rings on the indole warhead. The enzymatic assay showed that compounds with 4-ethyl and 4-isopropyl substitutions, <ce:bold>11a</ce:bold> and <ce:bold>11b</ce:bold> (<ce:cross-ref id="crosref0305" refid="fig2">Fig. 2</ce:cross-ref>), had significant inhibitory potency with IC<ce:inf loc="post">50</ce:inf> values of 0.097 and 0.094 μM against mutant EGFR<ce:sup loc="post">T790M</ce:sup>which were about 10 times more potent than erlotinib as the reference drug (IC<ce:inf loc="post">50</ce:inf> = 0.9 μM). In addition, these compounds showed comparable inhibitory activities to erlotinib against mutant EGFR<ce:sup loc="post">L858R</ce:sup>kinase. Molecular docking analysis, showed that an amino group acts as hydrogen bond donor in mutant EGFR<ce:sup loc="post">T790M</ce:sup> and interacted with Met793 while indole ring formed the hydrophobic interactions with various other hinge region residues [<ce:cross-ref id="crosref0310" refid="bib39">39</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec2.1.2" view="all">
                        <ce:label>2.1.2</ce:label>
                        <ce:section-title id="sectitle0050">2,4-Diamino substituted pyrimidine derivatives</ce:section-title>
                        <ce:para id="p0055" view="all">A series of <ce:italic>N</ce:italic>-aryl-<ce:italic>N′</ce:italic>-pyrimidin-4-yl urea derivatives were prepared as the selective inhibitors of double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup>based on the chemical structure of WZ4002. Several rounds of SAR study including changes in the both 2,4-anilino side chains were conducted to select the most potent and selective inhibitor. The preliminary biological screenings indicated that compound <ce:bold>12</ce:bold> with morpholine and urea functional groups (<ce:cross-ref id="crosref0315" refid="fig3">Fig. 3</ce:cross-ref>
                           <ce:float-anchor refid="fig3"/></ce:float-anchor>) had the highest activity and selectivity against double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> kinase (IC<ce:inf loc="post">50</ce:inf> = 4 nM with 22-fold selectivity over wild-type EGFR). Moreover, compound <ce:bold>12</ce:bold> potently inhibited the cellular proliferation of H1975 cells with IC<ce:inf loc="post">50</ce:inf> = 37 nM and phosphorylation of EGFR<ce:sup loc="post">L858R/T790M</ce:sup> with IC<ce:inf loc="post">50</ce:inf> = 41 nM [<ce:cross-ref id="crosref0320" refid="bib40">40</ce:cross-ref>]. A series of 2,4-dianilino-pyrmidines were designed as mutant and selective EGFR<ce:sup loc="post">T790M</ce:sup> inhibitors based on virtual screening procedure. Twelve newly synthesized derivatives with minimal cardiac toxicity were further screened through <ce:italic>in vitro</ce:italic> enzymatic and cell-based assays. Two compounds <ce:bold>13a</ce:bold> and <ce:bold>13b</ce:bold> (<ce:cross-ref id="crosref0325" refid="fig3">Fig. 3</ce:cross-ref>) were the most active derivatives against double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> with IC<ce:inf loc="post">50</ce:inf> values of 0.56 and 0.62 μM in enzymatic assay, which showed excellent cytotoxic effects against H1975 cells with IC<ce:inf loc="post">50s</ce:inf> = 0.88 and 0.92 μM, respectively [<ce:cross-ref id="crosref0330" refid="bib41">41</ce:cross-ref>]. The structural optimization of AZD929 led to the discovery of 2,4-diarylamino-pyrimidine derivatives with <ce:italic>ortho</ce:italic>-heterocycle substituted aniline, as mutant and selective EGFR inhibitors. A ring expansion strategy was used in order to synthesize more selective inhibitors. It seemed that the more flexible and bulky motif occupied the binding pocket was better than indole residue and subsequently higher selectivity and potency were achieved. The <ce:italic>in vitro</ce:italic> enzymatic and cell-based experiments revealed that compounds <ce:bold>14a</ce:bold> and <ce:bold>14b</ce:bold> (<ce:cross-ref id="crosref0335" refid="fig3">Fig. 3</ce:cross-ref>) exhibited good inhibitory activities against mutant EGFR<ce:sup loc="post">T790M/L858R</ce:sup>, with IC<ce:inf loc="post">50</ce:inf> value of 4.1 nM and potent anti-proliferative action comparable to AZD9291 in NCI-H1975 cells (IC<ce:inf loc="post">50</ce:inf> = 59 nM for <ce:bold>14a</ce:bold> and IC<ce:inf loc="post">50</ce:inf> = 68 nM for <ce:bold>14b)</ce:bold>. The western blotting assay confirmed that <ce:bold>14a</ce:bold> also effectively inhibited the phosphorylation of EGFR and its downstream signaling pathway and had significant tumor growth inhibition in NCI-H1975 xenograft model at the doses of 10 and 20 mg/kg [<ce:cross-ref id="crosref0340" refid="bib42">42</ce:cross-ref>]. With the aim to identify selective EGFR inhibitors, a series of 2,4-diarylamino-pyrimidines were investigated as new dual insulin-like Growth Factor 1 (IGF1R) and mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> inhibitors (IGF1R/EGFR<ce:sup loc="post">L858R/T790M</ce:sup> inhibitor). Compound <ce:bold>15</ce:bold> (<ce:cross-ref id="crosref0345" refid="fig3">Fig. 3</ce:cross-ref>) showed potent inhibitory activity against both kinases (IC<ce:inf loc="post">50s</ce:inf> = 0.013 and 0.038 μM, respectively), with strong anti-proliferative effects toward H1975-IGF1R cancer cells (IC<ce:inf loc="post">50</ce:inf> = 0.013 μM), and good kinase selectivity profile against a panel of 468 kinases. From the SAR study, it was determined that the “NH” group at the C-4 position and the lipophilic substitution (chloro-substitued) at the C-5 position of pyrimidine ring were critical for the inhibitory activity of compound <ce:bold>15</ce:bold> [<ce:cross-ref id="crosref0350" refid="bib43">43</ce:cross-ref>]. As potent mutant EGFR inhibitors, a series of azolediphenyl-pyrimidine derivatives were synthesized and assessed. Molecular simulations indicated that azole substituents formed a strong hydrogen bond with EGFR<ce:sup loc="post">T790M</ce:sup> which enhanced the binding affinity with EGFR<ce:sup loc="post">T790M</ce:sup> enzyme. Imidazole containing compounds <ce:bold>16a-c</ce:bold> (<ce:cross-ref id="crosref0355" refid="fig3">Fig. 3</ce:cross-ref>), exhibited the IC<ce:inf loc="post">50s</ce:inf> = 9.1, 3.3, and 9.0 nM, respectively against double mutant EGFR<ce:sup loc="post">T790M/L858R</ce:sup> kinases compared to rociletinib as the standard drug (IC<ce:inf loc="post">50</ce:inf> = 21.5 nM). These compounds also showed promising anti-proliferative activities against the NSCLC cell lines (harboring different mutants EGFR kinases such as A431 (wild-type EGFR), H1975 (double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup>), A549 (ras mutation), in particular, <ce:italic>N</ce:italic>-[3-[[5-chloro-2-[4-(1<ce:italic>H</ce:italic>-imidazol-1-ylmethyl)phenylamino]-4-pyrimidinyl]amino]phenyl]-2-propenamide <ce:bold>16b</ce:bold> showed the highest anticancer activity (IC<ce:inf loc="post">50</ce:inf> = 0.12 μM) against H1975 cell line harboring EGFR<ce:sup loc="post">L858R/T790M</ce:sup> mutation [<ce:cross-ref id="crosref0360" refid="bib44">44</ce:cross-ref>]. As the potent and selective mutant EGFR<ce:sup loc="post">T790M</ce:sup> inhibitors, a class of thiodiphenyl-pyrimidines were designed and synthesized. Structural modification was focused on both 2,4-diphenyl pyrimidine side chains by adding sulfur and oxygen heteroatoms. Two sulfur containing derivatives <ce:bold>17a</ce:bold> and <ce:bold>17b</ce:bold> (<ce:cross-ref id="crosref0365" refid="fig3">Fig. 3</ce:cross-ref>) possessed the highest activity and selectivity against double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> in enzymatic assay with the IC<ce:inf loc="post">50s</ce:inf> = 27.5 and 9.1 nM, respectively. Compound <ce:bold>17a</ce:bold> exhibited strong potency against H1975 in cell-based assay with the IC<ce:inf loc="post">50</ce:inf> = 0.074 μM, exhibiting more potency than rociletinib and gefitinib as the standard drugs [<ce:cross-ref id="crosref0370" refid="bib45">45</ce:cross-ref>]. A series of morpholine-substituted diphenyl-pyrimidines with flexible linkers were examined as potential EGFR inhibitors. The target compounds were designed based on the rociletinib, by replacement of piperazine core with morpholine ring and flexible linkers. Compound <ce:bold>18</ce:bold> (<ce:cross-ref id="crosref0375" refid="fig3">Fig. 3</ce:cross-ref>) displayed the highest activity and selectivity against double mutant EGFR<ce:sup loc="post">T790M/L858R</ce:sup> kinase (IC<ce:inf loc="post">50</ce:inf> = 0.71 nM) over wild-type EGFR (IC<ce:inf loc="post">50</ce:inf> = 448.7 nM). Furthermore, the mentioned derivative showed the highest inhibitory activity against H1975 cells harboring EGFR<ce:sup loc="post">T790M</ce:sup> mutation (IC<ce:inf loc="post">50</ce:inf> = 0.037 μM) and had excellent <ce:italic>in vivo</ce:italic> antitumor efficacy in an EGFR<ce:sup loc="post">T790M/L858R</ce:sup>-driven H1975 xenograft mouse model. SAR studies indicated that a flexible morpholine-substituted aniline at C-2 position of the pyrimidine core improved the selectivity property of compound <ce:bold>18</ce:bold> [<ce:cross-ref id="crosref0380" refid="bib46">46</ce:cross-ref>]. In an effort to find novel mutant EGFR<ce:sup loc="post">T790M</ce:sup> inhibitors, a number of <ce:italic>N</ce:italic>-alkylbenzamide-substituted diphenylpyrimidine derivatives were designed using a fragment-based drug design strategy. The most active inhibitors <ce:bold>19a-c</ce:bold> (<ce:cross-ref id="crosref0385" refid="fig3">Fig. 3</ce:cross-ref>) identified with significant anti-proliferative activity (against AsPC1, BxPC3, Panc1, MCF7 and H1975 cancer cells, EGFR<ce:sup loc="post">T790M</ce:sup> kinase inhibitory activity (IC<ce:inf loc="post">50s</ce:inf> = 3.89, 7.13 and 6.14 nM, respectively) and <ce:italic>in vivo</ce:italic> tumor growth inhibitory effects against AsPC1 cell xenograft mouse model [<ce:cross-ref id="crosref0390" refid="bib47">47</ce:cross-ref>]. Chen et al. reported the discovery and development of a series of 2,4-diamino-pyrimidines as dual ALK/EGFR kinase inhibitor. Based on the docking study results, the installment of electrophilic acrylamide group and different substitutions on the both C-2 and C-4 anilino warheads, led to the promising interactions with ALK and EGFR kinases and highly potent ALK/EGFR dual kinase inhibitors. The most promising compound <ce:bold>20</ce:bold> (<ce:cross-ref id="crosref0395" refid="fig3">Fig. 3</ce:cross-ref>) showed potent inhibitory activity against mutants EGFR kinases (IC<ce:inf loc="post">50</ce:inf> ranging from 3.6 to 82 nM) and the proliferation of EML4-ALK cancer cells (mutant EGFR-driven NSCLC cell lines). In addition, this derivative strongly inhibited the EGFR and ALK mediated signaling pathways, inducing apoptosis and cell cycle arrest at G0/G1 phase. The <ce:italic>in vivo</ce:italic> studies, showed that <ce:bold>20</ce:bold> significantly suppressed the tumor growth in H1975 and H3122 cell xenograft models [<ce:cross-ref id="crosref0400" refid="bib48">48</ce:cross-ref>]. New series of 2,4-diarylamino-pyrimidines were designed as covalent irreversible kinase inhibitors. The design strategy was laid on the attachment of F, Cl, phenyl and methyl at the α-position of acrylamide warhead in order to enhance the selectivity and safety index of irreversible inhibitors. Based on the biological results, compound <ce:bold>21</ce:bold>(<ce:cross-ref id="crosref0405" refid="fig3">Fig. 3</ce:cross-ref>) with α-chloro substituent was identified as the most potent double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> inhibitor (IC<ce:inf loc="post">50</ce:inf> = 3.9 nM) with great selectivity over EGFR<ce:sup loc="post">WT</ce:sup>. Furthermore, compound <ce:bold>21</ce:bold> exhibited good anti-proliferative activity against the gefitinib-resistant NCI-H1975 cells with IC<ce:inf loc="post">50</ce:inf> = 0.75 μM and induced cell cycle arrest at G0/G1 phase [<ce:cross-ref id="crosref0410" refid="bib49">49</ce:cross-ref>]. By applying three-step structure-based design approach, <ce:bold>23a</ce:bold> and <ce:bold>23b</ce:bold> (<ce:cross-ref id="crosref0415" refid="fig3">Fig. 3</ce:cross-ref>) were prepared based on the structure of previously reported reversible EGFR inhibitor <ce:bold>22</ce:bold>. The privileged tyrosine kinase inhibitory activity with IC<ce:inf loc="post">50s</ce:inf> = 4.1 and 3.2 nM, respectively against EGFR<ce:sup loc="post">L858RL/T790M</ce:sup>-driven NSCLC along with more than 60% selectivity over wild-type EGFR were observed. These selective inhibitors (<ce:bold>23a</ce:bold> and <ce:bold>23b</ce:bold>) also exhibited dose-dependent tumor growth suppression in a human NSCLC xenograft model [<ce:cross-ref id="crosref0420" refid="bib50">50</ce:cross-ref>]. Another series of 2,4-diamino-pyrimidine containing spiro structures were prepared and evaluated as dual EGFR and human epidermal growth factor receptor (HER2) inhibitors under 0.5 M drug concentration. Inspired by the structure of neratinib, the synthesized compounds were designed with different spiro groups such as spiro[indoline-3, 4-piperidine] and spiro [benzoxazine-2, 1-cyclopropane]. Based on the biochemical results, most of the compounds displayed strong inhibition toward EGFR<ce:sup loc="post">WT</ce:sup>. Compounds <ce:bold>24a</ce:bold> and <ce:bold>24b</ce:bold> (<ce:cross-ref id="crosref0425" refid="fig3">Fig. 3</ce:cross-ref>) showed the highest inhibitory effects against a panel of EGFR kinases especially against both mutants T790M and L858R EGFR kinases which were 31 times more stronger than neratinib as standard drug (IC<ce:inf loc="post">50</ce:inf> ranging from 0.05 to 0.2 μM) [<ce:cross-ref id="crosref0430" refid="bib51">51</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec2.1.3" view="all">
                        <ce:label>2.1.3</ce:label>
                        <ce:section-title id="sectitle0055">4,6-Diamino substituted pyrimidine derivatives</ce:section-title>
                        <ce:para id="p0060" view="all">The synthesis and biological evaluation of <ce:italic>N</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>4</ce:italic>
                           </ce:inf>,<ce:italic>N</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>6</ce:italic>
                           </ce:inf>-disubstituted pyrimidines as EGFR inhibitors for non-small cell lung cancer were reported by Zhang et al. Using molecular docking simulation results of previously reported inhibitors, 4,6-disubstituted pyrimidine was selected as a core structure to synthesize four series of derivatives. The designed compounds contained different substitutions on both C-4 and C-6 side chains. Based on the enzymatic and cellular evaluations of synthesized compounds, <ce:bold>25</ce:bold> (<ce:cross-ref id="crosref0435" refid="fig4">Fig. 4</ce:cross-ref>
                           <ce:float-anchor refid="fig4"/></ce:float-anchor>) was the most potent one with promising inhibitory results both in enzymatic and cellular assays (IC<ce:inf loc="post">50</ce:inf> less than 1.5 nM against H3255, A431, HCC827, PC9 and H197 cell lines and IC<ce:inf loc="post">50s</ce:inf> = 7.7 and 18 nM against mutants EGFR<ce:sup loc="post">delE746-A750</ce:sup> and EGFR<ce:sup loc="post">L858R</ce:sup>, respectively). This compound significantly induced apoptotic cell death and blocked the cell cycles at G2/M phase in above-mentioned cells (including H3255, A431, HCC827, and H1970 cell lines). Moreover, <ce:bold>25</ce:bold> demonstrated the <ce:italic>in vivo</ce:italic> antitumor activity in xenograft mouse model with the ability to inhibit the phosphorylation of EGFR and downstream AKT and ERK1/2 signaling pathways. Molecular docking simulation confirmed that methoxy substitutions on the C-6 aniline warhead formed hydrophobic contacts with EGFR which is helpful for the high selectivity and affinity of compound <ce:bold>25</ce:bold> [<ce:cross-ref id="crosref0440" refid="bib52">52</ce:cross-ref>]. In continuation, another series of 4,6-disubstitued pyrimidines containing 4-urea-aniline and 6-aniline with methoxy, alkyl or halogen substitutions, were designed through structural analysis of excellent EGFR and fibroblast growth factor receptor (FGFR) inhibitors. Compound <ce:bold>26</ce:bold> (<ce:cross-ref id="crosref0445" refid="fig4">Fig. 4</ce:cross-ref>) with 2,5-dimethoxy substituents on 6-aniline and 2,6-dichlorophenyl substitution on 4-urea aniline moieties was selected as the encouraging dual EGFR and FGFR inhibitor based on kinase testing and western blot analysis. Compound <ce:bold>26</ce:bold> showed more than 90% inhibition against wild-type and mutant EGFR kinases (including EGFR<ce:sup loc="post">WT</ce:sup>, EGFR<ce:sup loc="post">d746-750</ce:sup>, EGFR<ce:sup loc="post">T790M</ce:sup>, EGFR<ce:sup loc="post">L858R</ce:sup>) at 10 μM concentration, with significant anti-proliferation activity against H226 and HCC827 gefitinib-insensitive NSCLC cell lines (IC<ce:inf loc="post">50s</ce:inf> = 2.11 and 0.93 μM, respectively). Molecular docking study confirmed the formation of hydrogen bonding between NH of 4-phenylamine and the interaction of 2,6-dichlorophenyl substituted group with the surrounding hydrophobic pockets [<ce:cross-ref id="crosref0450" refid="bib53">53</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec2.1.4" view="all">
                        <ce:label>2.1.4</ce:label>
                        <ce:section-title id="sectitle0060">Miscellaneous derivatives</ce:section-title>
                        <ce:para id="p0065" view="all">A number of pyrimidine-benzothiazole hybrid system, were synthesized as new multi-targeted anticancer agents. To understand the SAR and kinase inhibitory activity of synthesized compounds, C-4 position of pyrimidine core has been modified with different aryl groups. Also, <ce:italic>N</ce:italic>-1 and C-6 positions of pyrimidine core underwent chemical substitutions and used to form five- or six-membered rings. Five compounds <ce:bold>27a-e</ce:bold> (<ce:cross-ref id="crosref0455" refid="fig5">Fig. 5</ce:cross-ref>
                           <ce:float-anchor refid="fig5"/></ce:float-anchor>) showed comparable cytotoxic activity regarding erlotinib in cell-based assays against A549, HCT116, PC3, MCF7, MDA-MB-231 cell lines with induction of apoptosis and cell cycle arrest at G2/M phase. Further, these compounds showed better inhibitory potency and selectivity towards EGFR and HER2 enzymes (IC<ce:inf loc="post">50</ce:inf> less than 1 μM) compared to lapatinib and 5-fluorouracil (5FU) as standards [<ce:cross-ref id="crosref0460" refid="bib54">54</ce:cross-ref>]. Two series of 5-amino-pyrimidines (contained amide and thiourea derivatives) were developed as EGFR inhibitors. In the designed compounds, phenoxy moieties were placed at the C-4 position of pyrimidine that interacted with the hydrophobic pocket at ATP binding site of EGFR. Based on the enzymatic and cell-based assays, compound 4-aryloxy-5-benzamidopyrimidine <ce:bold>28</ce:bold> (<ce:cross-ref id="crosref0465" refid="fig5">Fig. 5</ce:cross-ref>) was the most promising agent which inhibited the EGFR kinase with 95% and IC<ce:inf loc="post">50</ce:inf> = 1.05 μM. The anti-proliferative activity against different cancerous cells was also observed [<ce:cross-ref id="crosref0470" refid="bib55">55</ce:cross-ref>]. In continuation, this research group synthesized another series of 5-amino-pyrimidinamide including 5-benzamido- and 5-phenylureido-pyrimidine derivatives and examined their EGFR inhibitory activities. Based on the biological results, the amide analogs showed better EGFR inhibition than urea containing derivatives. The synthesized 5-benzamidopyrimidine derivatives <ce:bold>29a-c</ce:bold> (<ce:cross-ref id="crosref0475" refid="fig5">Fig. 5</ce:cross-ref>) showed favorable EGFR inhibitory activity with 76–91% inhibition at 100 μM concentration and IC<ce:inf loc="post">50</ce:inf> ranging from 2.37 to 5.37 μM. Further, significant anti-inflammatory results of compound <ce:bold>29c</ce:bold> have made it a suitable lead compound for the development of a novel class of anti-inflammatory EGFR inhibitors [<ce:cross-ref id="crosref0480" refid="bib56">56</ce:cross-ref>].</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0065">Heterocyclic-fused pyrimidine derivatives</ce:section-title>
                     <ce:section id="sec2.2.1" view="all">
                        <ce:label>2.2.1</ce:label>
                        <ce:section-title id="sectitle0070">Pyrrolo-pyrimidine derivatives</ce:section-title>
                        <ce:para id="p0070" view="all">The discovery of 1-{(3<ce:italic>R</ce:italic>,4<ce:italic>R</ce:italic>)-3-[({5-chloro-2-[(1-methyl-1<ce:italic>H</ce:italic>-pyrazol-4-yl)-amino]-7<ce:italic>H</ce:italic>-pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one <ce:bold>30</ce:bold> (<ce:bold>PF-06459988</ce:bold>) (<ce:cross-ref id="crosref0485" refid="fig6">Fig. 6</ce:cross-ref>
                           <ce:float-anchor refid="fig6"/></ce:float-anchor>) was reported by Cheng et al. in 2016 as potent and irreversible inhibitor of mutants EGFR<ce:sup loc="post">T790M</ce:sup>. A representative compound <ce:bold>30</ce:bold>, <ce:bold>PF-06459988</ce:bold> showed very high cellular potency against NSCLC cell lines harboring different mutations including H1975 (L858R/T790M), PC9-DRH (Del/T790M), H3255 (L858R), PC9 (Del), HCC827 (Del) cancer cells and excellent selectivity against wild-type EGFR cells A549 (EGFR<ce:sup loc="post">WT</ce:sup>) with IC<ce:inf loc="post">50s</ce:inf> = 13, 7, 21, 140, 90 and 5100 nM, respectively. The obtained anti-proliferative results by compound <ce:bold>30</ce:bold> were comparable with rociletinib, osimertinib and erlotinib as standard drugs. Molecular docking studies confirmed the hydrophobic interactions between pyrrolo-pyrimidine core with Met790 side chain, which provided high levels of T790M inhibitory potency, and selectivity. Also, an additional hydrogen bond interaction is indicated with the backbone carbonyl of Gln791 at the ATP binding site of the mutant EGFR<ce:sup loc="post">T790M</ce:sup> [<ce:cross-ref id="crosref0490" refid="bib57">57</ce:cross-ref>]. A number of compounds containing pyrrolo[2,3- <ce:italic>d</ce:italic>]pyrimidine scaffold were evaluated for their inhibitory effects against EGFR kinases. To determine the impact of various substituents on the inhibitory activity of synthesized derivatives, a number of electron-withdrawing and electron-donating groups were incorporated into varied positions. All the synthesized compounds had promising effects while 3-bromophenyl and 3-bromo-4-chlorophenylderivatives <ce:bold>31a</ce:bold> and <ce:bold>31b</ce:bold> (<ce:cross-ref id="crosref0495" refid="fig6">Fig. 6</ce:cross-ref>) demonstrated the highest EGFR enzymatic inhibitory with IC<ce:inf loc="post">50s</ce:inf> = 3.76 and 3.63 nM respectively. Further evaluation by western blotting assay confirmed that compound <ce:bold>31a</ce:bold> significantly inhibited all EGFR-mediated phosphorylation steps in BHY cells [<ce:cross-ref id="crosref0500" refid="bib58">58</ce:cross-ref>]. Another series of pyrrolo-pyrimidine derivatives were synthesized as EGFR kinase inhibitors. The design was focused on the attachment of chiral benzylamines at C-4 position of pyrimidine ring. The preliminary biological results showed that (<ce:italic>S</ce:italic>)-phenylglycinol containing derivatives had potent inhibitory activity. Further modifications on the C-5 position of pyrrolo-pyrimidine core, indicated that 3-hydroxy substituted derivative <ce:bold>32a</ce:bold> (<ce:cross-ref id="crosref0505" refid="fig6">Fig. 6</ce:cross-ref>) was the most potent analog with the IC<ce:inf loc="post">50</ce:inf> of 0.9 nM, comparable with erlotinib as the reference drug (IC<ce:inf loc="post">50</ce:inf> of 0.5 nM). In the cell-based study, 3-hydroxy and 4-methoxy derivatives, <ce:bold>32a</ce:bold> (IC<ce:inf loc="post">50</ce:inf> = 112 nM) and <ce:bold>32b</ce:bold> (<ce:cross-ref id="crosref0510" refid="fig6">Fig. 6</ce:cross-ref>) (IC<ce:inf loc="post">50</ce:inf> = 104 nM), showed potent inhibition of cell viability compared to erlotinib (IC<ce:inf loc="post">50</ce:inf> = 95 nM), against Ba/F3 cells harboring mutant EGFR<ce:sup loc="post">L858R/Ba/F3</ce:sup>. Also, these two derivatives were more selective than erlotinib as evidenced by the related assay in a panel of 50 kinases [<ce:cross-ref id="crosref0515" refid="bib59">59</ce:cross-ref>]. The benzo-anellated pyrrolo-pyrimidines were synthesized and evaluated as potential EGFR inhibitors. The structure-dependent affinities towards EGFR were discussed by attachment of varied substitution of both benzyl core and residue at the C-4 position of pyrrolo-pyrimidines moiety. All the synthesized compounds had sub-micromolar affinity towards EGFR in an ATP competition assay while compounds <ce:bold>33a</ce:bold> and <ce:bold>33b</ce:bold> (<ce:cross-ref id="crosref0520" refid="fig6">Fig. 6</ce:cross-ref>) showed promising results with IC<ce:inf loc="post">50s</ce:inf> = 0.09 and 0.08 μM, respectively. In addition, compound <ce:bold>33b</ce:bold> showed good anticancer screening results with interesting results against breast cancer cell lines ranging from 24 to 71% inhibition. Molecular docking simulations confirmed that the substituted benzyl ring was completely buried in a hydrophobic pocket by hydrogen bonds with Thr790 and Leu788 at the active site of EGFR [<ce:cross-ref id="crosref0525" refid="bib60">60</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.2" view="all">
                        <ce:label>2.2.2</ce:label>
                        <ce:section-title id="sectitle0075">Pyrazolo-pyrimidine containing compounds</ce:section-title>
                        <ce:para id="p0075" view="all">Three pyrazolo-pyrimidine containing compounds <ce:bold>34a-c</ce:bold> (<ce:cross-ref id="crosref0530" refid="fig7">Fig. 7</ce:cross-ref>
                           <ce:float-anchor refid="fig7"/></ce:float-anchor>) were designed and synthesized as covalent inhibitors to overcome the acquired drug resistance in EGFR tyrosine kinase domain. 4-Aminopyrazolo-pyrimidine decorated with <ce:italic>N</ce:italic>-acrylamido-piperidine was chosen as a core structure to provide hinge-binding at the ATP binding site of EGFR. Also, the effects of different bicyclic lipophilic moieties at C-3 position of pyrazole ring were assessed. The biological evaluation showed that all three compounds displayed significant inhibitory effects on H1975 cells (harbors EGFR<ce:sup loc="post">L858R/T790M</ce:sup> mutation) with GI<ce:inf loc="post">50</ce:inf> values of 0.21, 0.49, and 0.14 μm, respectively. The mentioned compounds <ce:bold>34a-c</ce:bold> also manifested significant inhibitory activities against mutant variants of EGFR kinases (L858R/T790M and L858R/T790M/C797S) while 2-napthalene derivative <ce:bold>34c</ce:bold>, was the most active one with IC<ce:inf loc="post">50</ce:inf> = 88 nM against triple mutant EGFR<ce:sup loc="post">L858R/T790M/C797S</ce:sup> comparable with CO-1686 and AZD9291 as the reference drugs. Further western blot analysis confirmed that these derivatives <ce:bold>34a-c</ce:bold> inhibited the phosphorylation of EGFR and its downstream signaling pathways in H1975 cells whilst showing low effect on EGFR<ce:sup loc="post">WT</ce:sup> cancer cell line (A431) [<ce:cross-ref id="crosref0535" refid="bib61">61</ce:cross-ref>]. Three series of 1<ce:italic>H</ce:italic>-pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidine derivatives were evaluated <ce:italic>in vitro</ce:italic> for their inhibitory activities against EGFR kinases. A number of modifications were done on the C-2 and C-4 position of pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidine ring as well as attachment of different linkers such as imino, hydrazono, keto-hydrazinyl, methylene-hydrazinyl, acetohydrazonoyl, thiosemicarbazide, semicarbazide and allylidene-hydrazinyl groups. Compounds <ce:bold>35a</ce:bold>, <ce:bold>35d</ce:bold> and <ce:bold>35h</ce:bold> (<ce:cross-ref id="crosref0540" refid="fig7">Fig. 7</ce:cross-ref>) potently inhibited EGFR<ce:sup loc="post">WT</ce:sup> at sub-micro molar IC<ce:inf loc="post">50</ce:inf> values comparable to that of erlotinib while compounds <ce:bold>35f</ce:bold> and <ce:bold>35g</ce:bold> (<ce:cross-ref id="crosref0545" refid="fig7">Fig. 7</ce:cross-ref>) exhibited comparable inhibitory to osimertinib towards mutant EGFR<ce:sup loc="post">T790M</ce:sup>. Also, anti-proliferative activities against three cancer cell lines bearing EGFR<ce:sup loc="post">WT</ce:sup> (MCF7, HepG2, A549) and two cancer cell lines bearing mutant EGFR<ce:sup loc="post">T790M</ce:sup> (H1975 and HCC827) showed that compounds <ce:bold>35c-e</ce:bold> and <ce:bold>35h-i</ce:bold> (<ce:cross-ref id="crosref0550" refid="fig7">Fig. 7</ce:cross-ref>) were the most potent anticancer agents against the EGFR<ce:sup loc="post">WT</ce:sup> containing cells, while compounds <ce:bold>35b</ce:bold>, <ce:bold>35f</ce:bold> and <ce:bold>35g</ce:bold> showed potential anti-proliferative activities against mutant EGFR<ce:sup loc="post">T790M</ce:sup> containing cells. Furthermore, compound <ce:bold>35h</ce:bold> was good apoptotic agent, which arrested HepG2 cell cycle at G0/G1 and G2/M phases [<ce:cross-ref id="crosref0555" refid="bib62">62</ce:cross-ref>]. A number of pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidine derivatives were evaluated against MCF7, A549 and HT29 cell lines. Compound <ce:italic>N-(</ce:italic>3,4,5-trimethoxybenzylidene)-2-(3,6-dimethyl-1-phenyl-1<ce:italic>H-</ce:italic>pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidin-4-yloxy)acetohydrazide <ce:bold>36</ce:bold> (<ce:cross-ref id="crosref0560" refid="fig7">Fig. 7</ce:cross-ref>) was the most potent antitumor agent with IC<ce:inf loc="post">50</ce:inf> values of 6.14, 9.09 and 5.36 μM respectively. Further, this compound revealed promising EGFR enzymatic inhibitory activity with the IC<ce:inf loc="post">50</ce:inf> = 4.18 μM [<ce:cross-ref id="crosref0565" refid="bib63">63</ce:cross-ref>]. A novel series of pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidines were evaluated against a panel of 60 human tumor cell lines. Compound <ce:bold>37</ce:bold> containing 4-flourophenyl (<ce:cross-ref id="crosref0570" refid="fig7">Fig. 7</ce:cross-ref>) displayed favorable antitumor activity against OVCAR-4, ACHN and NCIH460 cell lines with IC<ce:inf loc="post">50s</ce:inf> = 1.74, 5.53 and 4.44 μM, respectively. This compound also inhibited EGFR and ErbB2 kinases (IC<ce:inf loc="post">50s</ce:inf> = 0.18 and 0.25 μM, respectively) with induction of apoptosis through the increasing level of active caspase-3 and caused cell cycle arrest at G2/M phase of OVCAR4 cancer cells [<ce:cross-ref id="crosref0575" refid="bib64">64</ce:cross-ref>]. A number of pyrazolo-pyrimidine derivatives with 2-bromophenyl moiety were assessed against EGFR and vascular endothelial growth factor-2 (VEGFR-2) enzymes. Almost, all the tested compounds were more potent against HepG2 cancer cells than erlotinib and sorafenib as the reference drugs. Seven compounds showed comparable EGFR enzyme inhibitory activity to erlotinib (IC<ce:inf loc="post">50</ce:inf> less than 0.15 μM) while compounds <ce:bold>38a</ce:bold> with pyrazolo[4′, 3′:5,6]pyrano[2,3-<ce:italic>d</ce:italic>]pyrimidine and compound <ce:bold>38b</ce:bold> (<ce:cross-ref id="crosref0580" refid="fig7">Fig. 7</ce:cross-ref>) with pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidine core structure were more potent than erlotinib with IC<ce:inf loc="post">50s</ce:inf> = 0.06 and 0.09 μM, respectively [<ce:cross-ref id="crosref0585" refid="bib65">65</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.3" view="all">
                        <ce:label>2.2.3</ce:label>
                        <ce:section-title id="sectitle0080">Pyrido-pyrimidine based compounds</ce:section-title>
                        <ce:para id="p0080" view="all">A class of 2,4,6-trisubstitued pyrido[3,4-<ce:italic>d</ce:italic>]pyrimidine compounds were evaluated as mutant EGFR TK inhibitors. The most promising compound <ce:bold>39</ce:bold> (<ce:cross-ref id="crosref0590" refid="fig8">Fig. 8</ce:cross-ref>
                           <ce:float-anchor refid="fig8"/></ce:float-anchor>) strongly inhibited the proliferation of HCC827 and H1975 cancer cells with the IC<ce:inf loc="post">50</ce:inf> values of 0.04 and 0.40 μM. Moreover, with potent inhibitory activity against mutants EGFR<ce:sup loc="post">L858R</ce:sup> (IC<ce:inf loc="post">50</ce:inf> = 1.1 nM) and EGFR<ce:sup loc="post">L858R/T790M/C797S</ce:sup> (IC<ce:inf loc="post">50</ce:inf> = 7.2 nM) kinases was also observed for this compound. Further, this compound suppressed the EGFR phosphorylation in a dose-dependent manner and significantly induced apoptotic cell death in HCC827 cells [<ce:cross-ref id="crosref0595" refid="bib66">66</ce:cross-ref>]. A novel series of pyrido[3,4-<ce:italic>d</ce:italic>]pyrimidine containing derivatives were designed and investigated as EGFR degraders to overcome drug resistance, mediated by EGFR mutants. The designed EGFR degraders were varied by attachment of different linker at the C-4 and C-6 positions of pyrido[3,4-<ce:italic>d</ce:italic>]pyrimidine core. Based on the <ce:italic>in vitro</ce:italic> anti-proliferative results, the length and composition of the linker had significant effects on anti-proliferative activity. The newly synthesized compounds were more potent against HCC827 cells (harboring mutant EGFR<ce:sup loc="post">Del E746-A750</ce:sup>, also known as EGFR<ce:sup loc="post">Del19</ce:sup>), while they were significantly less toxic to H1975 (harboring EGFR<ce:sup loc="post">L858R/T790M</ce:sup>), A549 (harboring EGFR<ce:sup loc="post">WT</ce:sup>) and A431 (harboring EGFR<ce:sup loc="post">WT</ce:sup>) cells. Based on the western blotting analysis most of the tested compounds displayed moderate to potent degradation activity while compounds <ce:bold>40a</ce:bold> and <ce:bold>40b</ce:bold> (<ce:cross-ref id="crosref0600" refid="fig8">Fig. 8</ce:cross-ref>) showed the highest degradation of EGFR in a concentration dependent manner in HCC827 cells with DC<ce:inf loc="post">50</ce:inf> values of 45.2 and 34.8 nM, respectively. Further analysis confirmed that the mentioned compounds <ce:bold>40a</ce:bold> and <ce:bold>40b,</ce:bold> could significantly induce the apoptosis in HCC827 cells and arrested the cell cycle at G1 phase [<ce:cross-ref id="crosref0605" refid="bib67">67</ce:cross-ref>]. As another series of EGFR TK inhibitors, a number of compounds containing pyrido[3,4-<ce:italic>d</ce:italic>]pyrimidines were synthesized and evaluated. The design strategy was based on three parts including rigid phenylamino group at C-2, flexible linker, acrylamide warhead at C-4 and different substituents at C-6 positions of pyrido[3,4-<ce:italic>d</ce:italic>]pyrimidine core structure. The most representative compound <ce:bold>41</ce:bold> (<ce:cross-ref id="crosref0610" refid="fig8">Fig. 8</ce:cross-ref>) exhibited the anti-proliferation effects against HCC827 and H1975 cells with the IC<ce:inf loc="post">50</ce:inf> values of 0.02 and 0.49 μM, along with potent inhibitory activity against single and double mutants EGFR<ce:sup loc="post">L858R</ce:sup> (IC<ce:inf loc="post">50</ce:inf> = 1.7 nM) and EGFR<ce:sup loc="post">L858R/T790M</ce:sup> (IC<ce:inf loc="post">50</ce:inf> = 23.3 nM) kinases. Also, this compound suppressed EGFR phosphorylation in HCC827 and H1975 cell lines and significantly induced the apoptosis in HCC827 cells. Further <ce:italic>in vivo</ce:italic> study confirmed that compound <ce:bold>41</ce:bold> remarkably inhibited cancer growth in established HCC827 xenograft mouse model at 50 mg/kg [<ce:cross-ref id="crosref0615" refid="bib68">68</ce:cross-ref>]. Another series of pyrido[3,4-<ce:italic>d</ce:italic>]pyrimidines as EGFR degraders were designed and evaluated by Zhang et al. The designed compounds were synthesized with different length of linkers attached to piperazine ring at the C-2 position of pyrido[3,4-<ce:italic>d</ce:italic>]pyrimidines core structure. The biochemical assays showed that compound <ce:bold>42</ce:bold> (<ce:cross-ref id="crosref0620" refid="fig8">Fig. 8</ce:cross-ref>) effectively and selectively degraded double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> in a dose-dependent manner with the DC<ce:inf loc="post">50</ce:inf> value of 5.9 nM, while did not exhibit obvious degradation on the wild-type EGFR in A431 cells. Further investigation also demonstrated that compound <ce:bold>42</ce:bold> selectively suppressed the downstream signaling of EGFR in H1975 cells with EGFR<ce:sup loc="post">L858R/T790M</ce:sup> mutation [<ce:cross-ref id="crosref0625" refid="bib69">69</ce:cross-ref>]. As selective mutant EGFR<ce:sup loc="post">T790M</ce:sup> inhibitors, a series of pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-7-ones were synthesized and evaluated. Structural optimization was done on the C-2 and N-4 positions of pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin core with the aim of improving pharmacokinetic parameters. Among the synthesized derivatives, compound <ce:bold>43</ce:bold> (<ce:cross-ref id="crosref0630" refid="fig8">Fig. 8</ce:cross-ref>) represented not only potent enzymatic and anti-proliferative activities against double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> kinase and H1975 cells (IC<ce:inf loc="post">50</ce:inf> values of 2 and 40 nM, respectively) but also inhibited the phosphorylation of EGFR and its downstream signaling pathways in H1975 cells [<ce:cross-ref id="crosref0635" refid="bib70">70</ce:cross-ref>]. A series of 5-methylpyrimido-pyridone derivatives were designed, synthesized and evaluated as promising triple mutant EGFR<ce:sup loc="post">L858R/T790M/C797S</ce:sup> inhibitors. 5-Methylpyrimido-pyridone was selected as core structure based on the molecular modeling of previously reported mutant EGFR<ce:sup loc="post">/T790M/C797S</ce:sup> inhibitors <ce:bold>JND3229</ce:bold>. The best result was obtained by compound <ce:bold>44</ce:bold> (<ce:cross-ref id="crosref0640" refid="fig8">Fig. 8</ce:cross-ref>), which exhibited potent triple mutant EGFR<ce:sup loc="post">L858R/T790M/C797S</ce:sup> inhibitory activity (IC<ce:inf loc="post">50</ce:inf> = 27.5 nM) and selectivity over EGFR<ce:sup loc="post">WT</ce:sup> (IC<ce:inf loc="post">50</ce:inf> more than 1.0 μM). Further, the observed target selectivity of the compound <ce:bold>44</ce:bold> was validated by computational investigation, which mainly relied on the hydrophobic nature of the Met790 residue in the T790M/C797S mutant protein bonded to 5-Methylpyrimido-pyridone core [<ce:cross-ref id="crosref0645" refid="bib71">71</ce:cross-ref>]. The activity of another class of pyrido-pyrimidinone containing compounds were evaluated against HepG2, PC-3, and HCT-116 cell lines. The title compounds were designed based on the structures of previously reported inhibitors with varied substituents on the C-2 of pyrido-pyrimidinone ring. Among the synthesized compounds, 2-(3-methyl-5-oxo-2,5-dihydro-1<ce:italic>H</ce:italic>-pyrazol-1-yl)-5-phenyl-7-(pyridin-3-yl)pyrido-[2,3-<ce:italic>d</ce:italic>]-pyrimidin-4(3<ce:italic>H</ce:italic>)-one <ce:bold>45</ce:bold> (<ce:cross-ref id="crosref0650" refid="fig8">Fig. 8</ce:cross-ref>) showed the highest anticancer activity against HepG2 cells with IC<ce:inf loc="post">50</ce:inf> = 0.5 μM <ce:italic>vs</ce:italic> doxorubicin with IC<ce:inf loc="post">50</ce:inf> = 0.6 μM. Further <ce:italic>in vitro</ce:italic> assessment confirmed that the representative compound <ce:bold>45</ce:bold> highly inhibited a number of protein kinases (AKT1, AKT2, BRAF (V600E), CDK2/cyclin A1, CHK1, EGFR, PDGFRβ, and c-RAF) with the highest inhibition recorded against EGFR by more than 97% at 100 μM concentration [<ce:cross-ref id="crosref0655" refid="bib72">72</ce:cross-ref>]. A series of substituted pyrido[2,3-<ce:italic>d</ce:italic>] pyrimidinone were evaluated against HepG2, PC3, HCT116, MCF7 and A549 cancer cell lines. The design strategy was based on the attachment of different aryl groups to C-5 and C-7 positions of pyrido[2,3-<ce:italic>d</ce:italic>] pyrimidinone with pyrazole or hydrazine at the C-2 position. 7-(4-Chlorophenyl)-2-(3-methyl-5-oxo-2,3-dihydro-1<ce:italic>H</ce:italic>-pyrazol-1-yl)-5-(<ce:italic>p</ce:italic>-tolyl)-pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidin-4(3<ce:italic>H</ce:italic>)-one <ce:bold>46</ce:bold> (<ce:cross-ref id="crosref0660" refid="fig8">Fig. 8</ce:cross-ref>) exhibited strong anticancer activity against HepG2, PC3 and HCT116 cancer cells (IC<ce:inf loc="post">50s</ce:inf> = 0.3, 6.6 and 7 μM, respectively) which was more potent than doxorubicin as the standard drug. Further, this compound showed promising EGFR kinase inhibitory activity, at 50 and 100 μM concentrations with 81 and 86% inhibition, respectively [<ce:cross-ref id="crosref0665" refid="bib73">73</ce:cross-ref>]. Another series of pyrido[2,3-<ce:italic>d</ce:italic>]pyrimidines were examined as small molecules EGFR inhibitors. The target compounds were designed based on the structures of quinazoline-based FDA approved drugs such as gefitinib and erlotinib. The strategy was directed towards carrying out the chemical modifications on the general features of anilinoquinazoline scaffold. Also, the effects of sulfur and oxygen heteroatoms on the C-2 position of pyrido[2,3- <ce:italic>d</ce:italic>]pyrimidines were evaluated. The best results were seen by compound <ce:bold>47</ce:bold> (<ce:cross-ref id="crosref0670" refid="fig8">Fig. 8</ce:cross-ref>) with 81.7% inhibition at 25 nM concentration in an enzymatic kinase assay and IC<ce:inf loc="post">50</ce:inf> = 8.4 nM against MCF-7 cells in cell-based assay which was comparable to sorafenib as the reference drug (IC<ce:inf loc="post">50</ce:inf> = 7.66 nM). This compound also showed promising antitumor activity against leukemia and renal cancer cell lines [<ce:cross-ref id="crosref0675" refid="bib74">74</ce:cross-ref>]. The synthesis and biological evaluation of 4-anilino-dihydropyrido[4,3-<ce:italic>d</ce:italic>]pyrimidines were reported by zhang et al. Based on the biological results, most of the synthesized compounds revealed significant anti-proliferative activity against A549, HT29, H460, and H1975 cancer cell lines. Compound methyl 4-((3-chlorophenyl)amino)-7,8-dihydropyrido[4,3-<ce:italic>d</ce:italic>]pyrimidine-6(5<ce:italic>H</ce:italic>)-carboxylate <ce:bold>48</ce:bold> (<ce:cross-ref id="crosref0680" refid="fig8">Fig. 8</ce:cross-ref>) was the most representative one with potent EGFR inhibitory activity in enzymatic assays (IC<ce:inf loc="post">50</ce:inf> = 14.8 nM) superior to gefitinib (IC<ce:inf loc="post">50</ce:inf> = 28.6 nM) as the reference drug. Also, Western blot assay confirmed the inhibition of EGFR and EGFR phosphorylation in the A549 cells by compound <ce:bold>48</ce:bold> at 100 and 300 nM concentrations [<ce:cross-ref id="crosref0685" refid="bib75">75</ce:cross-ref>]. Another series of tetrahydropyrido[4,3-<ce:italic>d</ce:italic>]pyrimidines were screened as dual EGFR and VEGFR-2 inhibitors. In cellular level, compounds <ce:bold>49a</ce:bold> and <ce:bold>49b</ce:bold> (<ce:cross-ref id="crosref0690" refid="fig8">Fig. 8</ce:cross-ref>) displayed significant antitumor activities against A549, MKN45 and SGC cancer cells (IC<ce:inf loc="post">50</ce:inf> less than 4.4 μM). Furthermore, these two derivatives (<ce:bold>49a</ce:bold> and <ce:bold>49b</ce:bold>) showed promising EGFR kinase inhibitory in enzymatic assay with IC<ce:inf loc="post">50</ce:inf> values of 18.0 and 24.2 nM, respectively which was better than gefitinib [<ce:cross-ref id="crosref0695" refid="bib76">76</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.4" view="all">
                        <ce:label>2.2.4</ce:label>
                        <ce:section-title id="sectitle0085">Pyrimido-pyrimidine derivatives</ce:section-title>
                        <ce:para id="p0085" view="all">In an effort to find novel mutant EGFR inhibitors, a series of pyrimido[4,5-<ce:italic>d</ce:italic>]pyrimidine-2,4(1<ce:italic>H</ce:italic>,3<ce:italic>H</ce:italic>)-diones were designed with hydrophobic groups at different lengths and volumes at N-6 position of pyrimido[4,5-<ce:italic>d</ce:italic>]pyrimidine core structure. Compound <ce:bold>50</ce:bold> (<ce:cross-ref id="crosref0700" refid="fig9">Fig. 9</ce:cross-ref>
                           <ce:float-anchor refid="fig9"/></ce:float-anchor>) was the most potent compound with significant inhibitory activity and selectivity in both <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> levels. Compound <ce:bold>50</ce:bold> displayed encouraging results against mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> (IC<ce:inf loc="post">50</ce:inf> = 0.3 nM) and H1975 cells (IC<ce:inf loc="post">50</ce:inf> = 44 nM) with outstanding antitumor efficiency in H1975 xenograft mouse model [<ce:cross-ref id="crosref0705" refid="bib77">77</ce:cross-ref>]. The identification of pyrimido-pyrimidinone derivative <ce:bold>51</ce:bold> JND3229 (<ce:cross-ref id="crosref0710" refid="fig9">Fig. 9</ce:cross-ref>) as highly potent mutant EGFR<ce:sup loc="post">C797S</ce:sup> inhibitor was reported in 2018. Compound <ce:bold>51</ce:bold> strongly inhibited the proliferation of BaF3 cells (harboring EGFR<ce:sup loc="post">L858R/T790M/C797S</ce:sup> and EGFR<ce:sup loc="post">19D/T790M/C797S</ce:sup> mutations, (more potent than AZD9291 as the standard) and NCI-H1975 cells (harboring EGFR<ce:sup loc="post">L858R/T790M</ce:sup> mutation (more potent than brigatinib as the reference drug) with IC<ce:inf loc="post">50s</ce:inf> = 0.51, 0.32 and 0.31 μM, respectively. Further <ce:italic>in vivo</ce:italic> assays confirmed the efficacy of <ce:bold>51</ce:bold> as mono-drug anticancer in a xenograft mouse model of BaF3 cells. The molecular docking study confirmed the hydrogen binding and hydrophobic interactions between compound <ce:bold>51</ce:bold> and ATP binding site of mutant EGFR<ce:sup loc="post">C797S</ce:sup> [<ce:cross-ref id="crosref0715" refid="bib78">78</ce:cross-ref>]. A series of 2-oxo-3,4-dihydropyrimido[4,5-<ce:italic>d</ce:italic>]pyrimidines were designed based on the structure of <ce:bold>51</ce:bold>. The SAR study was first investigated on different linkers attached to N-8 position and then on the substituents on the phenyl piperazine warhead. The novel compounds had promising EGFR<ce:sup loc="post">L858R/T790M/C797S</ce:sup> kinase inhibitory activity while the best result was obtained by compound <ce:bold>52</ce:bold> (<ce:cross-ref id="crosref0720" refid="fig9">Fig. 9</ce:cross-ref>) with the IC<ce:inf loc="post">50</ce:inf> = 3.1 nMin the enzymatic assay and IC<ce:inf loc="post">50s</ce:inf> = 0.29 and 0.31 μM against BaF3 cells harboring EGFR<ce:sup loc="post">L858R/T790M/C797S</ce:sup> and EGFR<ce:sup loc="post">19D/T790M/C797S</ce:sup> mutations in cell-based assays [<ce:cross-ref id="crosref0725" refid="bib79">79</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.5" view="all">
                        <ce:label>2.2.5</ce:label>
                        <ce:section-title id="sectitle0090">Furo-pyrimidine based compounds</ce:section-title>
                        <ce:para id="p0090" view="all">A number of 6-aryl-furo[2,3-<ce:italic>d</ce:italic>]pyrimidine-4-amines were designed with the modifications on the 4-amino and 6-aryl functional groups. Two Compounds having a chiral 4-benzylamino group <ce:bold>53a</ce:bold> and <ce:bold>53b</ce:bold> (<ce:cross-ref id="crosref0730" refid="fig10">Fig. 10</ce:cross-ref>
                           <ce:float-anchor refid="fig10"/></ce:float-anchor>) showed the highest EGFR inhibitory activity (IC<ce:inf loc="post">50s</ce:inf> = 0.4 and 0.6 nM) with comparable potency to erlotinib. The synthesized compounds were also evaluated for their inhibitory effects in cell-based assays. The mentioned compounds <ce:bold>53a</ce:bold> and <ce:bold>53b</ce:bold> also showed high activity towards Ba/F3 cells harbors mutant EGFR<ce:sup loc="post">L858R</ce:sup> with IC<ce:inf loc="post">50</ce:inf> values of 217 and 196 nM, respectively [<ce:cross-ref id="crosref0735" refid="bib80">80</ce:cross-ref>]. Four series of 4-anilino-furo[2,3-<ce:italic>d</ce:italic>]pyrimidines containing acid, amid, ester and alcohol functional group on the 5-position of the core structure, were designed and evaluated as EGFR kinase inhibitors. Based on the <ce:italic>in vitro</ce:italic> enzymatic assay, acid containing compounds such as 3-chloro <ce:bold>54a</ce:bold>, 3-bromo <ce:bold>54b</ce:bold> derivatives and the lapatinib analog <ce:bold>54d</ce:bold> (<ce:cross-ref id="crosref0740" refid="fig10">Fig. 10</ce:cross-ref>) were the most potent EGFR inhibitors (IC<ce:inf loc="post">50</ce:inf> less than 1 μM). I<ce:italic>n vitro</ce:italic> anti-proliferative assay revealed that ester containing compound <ce:bold>54c</ce:bold> and its acid analog <ce:bold>54d</ce:bold> showed significant variation of results against A549 cell line with IC<ce:inf loc="post">50s</ce:inf> = 0.5 and 21.4 μM, respectively. Further <ce:italic>in vivo</ce:italic> results indicated the antitumor activity of <ce:bold>54b</ce:bold> and <ce:bold>54c</ce:bold> against EAC (Ehrlich Ascites Carcinoma) solid tumor model which was comparable to that of gefitinib at 10 mg/kg dose [<ce:cross-ref id="crosref0745" refid="bib81">81</ce:cross-ref>]. The structural optimization on the furano-pyrimidine containing derivatives <ce:bold>55a</ce:bold> and <ce:bold>55b</ce:bold> [<ce:cross-ref id="crosref0750" refid="bib82">82</ce:cross-ref>,<ce:cross-ref id="crosref0755" refid="bib83">83</ce:cross-ref>] led to the design and synthesis of (S)-2-phenylglycinol containing compounds with various acrylamides as the Michel acceptor at the C-3 position of the furan ring. A clinical drug candidate <ce:bold>55c</ce:bold> (DBPR112) (<ce:cross-ref id="crosref0760" refid="fig10">Fig. 10</ce:cross-ref>) was the most potent and selective double mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> inhibitor. Compound <ce:bold>55c</ce:bold> (DBPR112) exhibited promising EGFR and HER2 inhibitory activity (comparable with poziotinib). Further, these compounds expressed good selectivity over wild-type EGFR. Compound <ce:bold>55c</ce:bold> (DBPR112) is currently under investigation as the new drug on phase I clinical trials in Taiwan [<ce:cross-ref id="crosref0765" refid="bib84">84</ce:cross-ref>]. Design, synthesis and biological evaluation of 4-aminoindazolyl-dihydrofuro[3,4-<ce:italic>d</ce:italic>]pyrimidines <ce:bold>56a-c</ce:bold> were reported by Hanan et al. The structure-based design focused on improving pharmacokinetic properties of synthesized derivatives through metabolite identification. In this regards, a large number of inhibitors were designed by attachment of different heterocycles on C-2 and C-4 positions of pyrimidine ring. Based on the results, compounds <ce:bold>56a-c</ce:bold> (<ce:cross-ref id="crosref0770" refid="fig10">Fig. 10</ce:cross-ref>) showed remarkable inhibitory activity (IC<ce:inf loc="post">50</ce:inf> less than 9 nM) against mutant EGFR kinases. The compound <ce:bold>56c</ce:bold> exhibited moderate activity in the cell-based assay (against H1975 pEGFR with IC<ce:inf loc="post">50</ce:inf> = 0.37 μM) which was comparable to erlotinib as the reference drug [<ce:cross-ref id="crosref0775" refid="bib85">85</ce:cross-ref>]. A number of 4-substituted-5-methyl-furo[2,3-<ce:italic>d</ce:italic>]pyrimidines were synthesized and evaluated as EGFR kinase inhibitors. To understand the structural features of 5-methyl-furo[2,3-d]pyrimidines, designed compounds were varied by substituted aryl groups at the C-4 position of pyrimidine core. Compound <ce:bold>57</ce:bold> (<ce:cross-ref id="crosref0780" refid="fig10">Fig. 10</ce:cross-ref>) showed the highest EGFR kinase inhibition in enzymatic assay with IC<ce:inf loc="post">50</ce:inf> = 3.1 nM and potent anti-proliferative activity toward A431 cells in cell-based assay (IC<ce:inf loc="post">50</ce:inf> = 1 nM) [<ce:cross-ref id="crosref0785" refid="bib86">86</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.6" view="all">
                        <ce:label>2.2.6</ce:label>
                        <ce:section-title id="sectitle0095">Thieno-pyrimidine derivatives</ce:section-title>
                        <ce:para id="p0095" view="all">Forty four thieno[2,3-<ce:italic>d</ce:italic>]pyrimidine derivatives were evaluated as EGFR TK inhibitors. The design strategy focused on the variation at the 4-amino and the 6-aryl groups considering both potency and ADME properties. Based on the ADME profiles (absorption, distribution, metabolism, excretion and toxicology) and biological activities, those compounds containing benzylamines were found superior to aniline hybrid structures. Compound <ce:bold>58</ce:bold> (<ce:cross-ref id="crosref0790" refid="fig11">Fig. 11</ce:cross-ref>
                           <ce:float-anchor refid="fig11"/></ce:float-anchor>) showed similar activity compared to erlotinib in both cellular and enzymatic assays (IC<ce:inf loc="post">50s</ce:inf> = 0.3 and 0.09 μM against EGFR-driven cell lines A431and PC9, respectively and IC<ce:inf loc="post">50</ce:inf> = 0.3 μM against EGFR enzyme). In addition, the mentioned compound showed improved solubility and metabolic stability with less lethal toxicity than erlotinib [<ce:cross-ref id="crosref0795" refid="bib87">87</ce:cross-ref>]. A series of 6-phenylthieno[2,3-<ce:italic>d</ce:italic>]pyrimidine were developed based on binding mode of the marketed dual EGFR/HER2 inhibitor, lapatinib. The best result were obtained by compound <ce:bold>59</ce:bold> (<ce:cross-ref id="crosref0800" refid="fig11">Fig. 11</ce:cross-ref>) against EGFR and HER2 with IC<ce:inf loc="post">50</ce:inf> values of 91.7 nM and 1.2 μM, respectively. In addition, compound <ce:bold>59</ce:bold> strongly inhibited the proliferation of cancer cells (A431, MDA-MBA361, SKBr3and lapatinib-resistant human cellsNCI-H1975) which inactivated the EGFR phosphorylation and its downstream AKT/mTOR/S6 signaling pathway in a concentration-dependent manner [<ce:cross-ref id="crosref0805" refid="bib88">88</ce:cross-ref>]. A series of 4-trimethoxyanilino thieno[3,2-<ce:italic>d</ce:italic>]-pyrimidine derivatives were screened as novel dual EGFR kinase and microtubule polymerization inhibitors. The target compounds were designed as multi-targeted inhibitors by maintaining the 3,4,5-trimethoxyanilino group at the C-4 position of thieno[2,3-d]pyrimidine core. The most representative compound <ce:bold>60a</ce:bold> (<ce:cross-ref id="crosref0810" refid="fig11">Fig. 11</ce:cross-ref>) manifested potent anti-proliferative activity toward all tested cell lines (A549, HeLa, HT29, Jurkat, RS4; 11) with IC<ce:inf loc="post">50</ce:inf> values ranging from 0.001 to 0.02 μM. The compound <ce:bold>60a</ce:bold> showed the highest inhibition of tubulin polymerization with IC<ce:inf loc="post">50</ce:inf> = 0.71 μM, while compound <ce:bold>60b</ce:bold> (<ce:cross-ref id="crosref0815" refid="fig11">Fig. 11</ce:cross-ref>) was found to possess the highest inhibitory effect against EGFR kinase (IC<ce:inf loc="post">50</ce:inf> = 2.5 nM) compared with erlotinib as the standard drug (IC<ce:inf loc="post">50</ce:inf> = 1.5 nM) [<ce:cross-ref id="crosref0820" refid="bib89">89</ce:cross-ref>]. Two novel series of thieno[2,3-<ce:italic>d</ce:italic>]pyrimidine and thieno[3,2-<ce:italic>d</ce:italic>] pyrimidines were synthesized and evaluated against PC3, MDA-MB-231, A549, and HeLa cell lines. Thieno-pyrimidine was selected as the core structure with substituted 4-arylamino ring according to the bioisosterism strategy. Further, α, β-unsaturated carbonyl group was added to the C-6 position of thieno-pyrimidine core structure in order to improve binding affinity to EGFR through covalent interaction. Two compounds <ce:bold>61a</ce:bold> and <ce:bold>61b</ce:bold> (<ce:cross-ref id="crosref0825" refid="fig11">Fig. 11</ce:cross-ref>) with promising results against HeLa cell line (IC<ce:inf loc="post">50s</ce:inf> = 4 and 33 nM, respectively) were studied by western blot analysis which revealed acceptable results of suppressing the EGFR and its downstream signaling pathways (p-EGFR/p-ERK1/2). In addition, these two compounds induced cell death <ce:italic>via</ce:italic> apoptosis and arrested HeLa cell growth in G0 phase [<ce:cross-ref id="crosref0830" refid="bib90">90</ce:cross-ref>]. A number of 4-anilinothieno[2,3-<ce:italic>d</ce:italic>]pyrimidines with several benzyloxy aniline moiety attached to the aromatic and hetero-aromatic tails were synthesized and evaluated as dual EGFR/HER-2 kinase inhibitors. The modification on the thieno-pyrimidine core led to the 5,6,7,8-tetrahydrobenzothieno[2,3-<ce:italic>d</ce:italic>]pyrimidine containing compounds, among which compound <ce:bold>62</ce:bold> with 3-chloro-4-[(3-fluorobenzyl)oxy]aniline was the most promising EGFR/HER-2 kinase inhibitors with 100% of both enzymatic inhibitions and IC<ce:inf loc="post">50</ce:inf> = 0.2 and 0.5 μM against EGFR and HER-2 kinase, respectively (<ce:cross-ref id="crosref0835" refid="fig11">Fig. 11</ce:cross-ref>). The significant cell growth inhibition against ovarian, breast, NSCLC and renal cancer cell lines ranging from 42 to 81% was observed for compound <ce:bold>62</ce:bold> [<ce:cross-ref id="crosref0840" refid="bib91">91</ce:cross-ref>]. A number of thieno[2,3-<ce:italic>d</ce:italic>]pyrimidine fused with cyclohexyl were designed with varied hydrophobic moieties such as substituted phenyl, aromatic, and fused heterocyclic aromatic structures with different length of linkers on the 4-anilino warhead. Based on the <ce:italic>in vitro</ce:italic> cytotoxicity, compounds <ce:bold>63a-c</ce:bold> (<ce:cross-ref id="crosref0845" refid="fig11">Fig. 11</ce:cross-ref>) exhibited the highest activities against HepG2, HCT116, MCF7 and A431 cell lines with IC<ce:inf loc="post">50</ce:inf> values ranging from 7.59 to 16.0 μM comparable to erlotinib (IC<ce:inf loc="post">50</ce:inf> ranging from 4.99 to 13.91 μM). Based on the <ce:italic>in vitro</ce:italic> EGFR<ce:sup loc="post">WT</ce:sup>, EGFR<ce:sup loc="post">T790M</ce:sup> and HER-2 kinase inhibitory assays, compounds <ce:bold>63a</ce:bold> and <ce:bold>63c</ce:bold> showed similar potency compared to the standard drug erlotinib, which was confirmed by good binding pattern of the mentioned compounds with the prospective target, EGFR<ce:sup loc="post">WT</ce:sup> and mutant EGFR<ce:sup loc="post">T790M</ce:sup> in molecular docking studies. Further studies confirmed that the most representative compound <ce:bold>63c</ce:bold> induced apoptotic cell death and arrested G2/M phase of MCF-7 cell cycle [<ce:cross-ref id="crosref0850" refid="bib92">92</ce:cross-ref>]. A series of 6,7,8,9-tetrahydro-5<ce:italic>H</ce:italic>-cycloheptan [<ce:cross-ref id="crosref0855" refid="bib4">4</ce:cross-ref>,<ce:cross-ref id="crosref0860" refid="bib5">5</ce:cross-ref>]-thieno[2,3-<ce:italic>d</ce:italic>]pyrimidine derivatives were synthesized as dual inhibitors of EGFR and VEGFR-2, and investigated against MCF-7 cell line. Most of the compounds showed significant anticancer activity while compound <ce:bold>64</ce:bold> (<ce:cross-ref id="crosref0865" refid="fig11">Fig. 11</ce:cross-ref>) with IC<ce:inf loc="post">50</ce:inf> = 0.66 μM was the most potent derivative with 1.73- and 4.64-folds more potency than both erlotinib and doxorubicin as the reference drugs. Also, <ce:bold>64</ce:bold> exhibited potent EGFR inhibitory activity with IC<ce:inf loc="post">50</ce:inf> = 0.028 μM which caused cellular apoptosis and cell cycle arrest at G2/M phase in MCF7 cells [<ce:cross-ref id="crosref0870" refid="bib93">93</ce:cross-ref>]. The preliminary biological results demonstrated that compounds <ce:bold>65a</ce:bold> (<ce:cross-ref id="crosref0875" refid="fig11">Fig. 11</ce:cross-ref>) (with IC<ce:inf loc="post">50</ce:inf> values of 4.34 and 4.79 μM) and <ce:bold>65b</ce:bold> (<ce:cross-ref id="crosref0880" refid="fig11">Fig. 11</ce:cross-ref>) (with IC<ce:inf loc="post">50</ce:inf> values of 4.34 and 3.79 μM) were the most potent anti-proliferative against A549 and A431 cell lines with strong activity and selectivity against double mutant EGFR<ce:sup loc="post">T790M/L858R</ce:sup> kinase (IC<ce:inf loc="post">50s</ce:inf> = 15.3 and 13.6 nM, respectively). Further studies confirmed that compound <ce:bold>65b</ce:bold> induced late apoptosis cell death in A431 cancer cells in a dose-dependent manner [<ce:cross-ref id="crosref0885" refid="bib94">94</ce:cross-ref>]. Novel series of thieno[3,2-<ce:italic>d</ce:italic>]pyrimidines were designed based on the structure of olmutinib and evaluated as mutant EGFR TK inhibitors. Five compounds <ce:bold>66a-e</ce:bold> (<ce:cross-ref id="crosref0890" refid="fig11">Fig. 11</ce:cross-ref>) indicated strong inhibition activity toward mutant EGFR<ce:sup loc="post">L858R/T790M</ce:sup> (IC<ce:inf loc="post">50s</ce:inf> ranging from 0.11 to 0.25 μM) with good selectivity over wild-type EGFR (IC<ce:inf loc="post">50</ce:inf> more than 10 μM). The prototype compounds <ce:bold>66a-e</ce:bold> significantly inhibited the proliferation of cancer cell lines harboring different mutants status, including H1975 (EGFR<ce:sup loc="post">L858R/T790M</ce:sup>), A549 (EGFR<ce:sup loc="post">WT</ce:sup>) and PC9 (EGFR<ce:sup loc="post">del19</ce:sup>) with comparable potency to gefitinib, erlotinib and olmutinib as standard drugs. Further analysis in H1975 lung cancer cells confirmed that compound <ce:bold>66e</ce:bold> could significantly inhibit the colony formation, wound healing and the expression of phosphorylate EGFR and its downstream ERK [<ce:cross-ref id="crosref0895" refid="bib95">95</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec2.2.7" view="all">
                        <ce:label>2.2.7</ce:label>
                        <ce:section-title id="sectitle0100">Thiopyrano-pyrimidine derivatives</ce:section-title>
                        <ce:para id="p0100" view="all">As AZD9291 derivatives, a number of thiopyrano-pyrimidines containing differently substituted acrylamide structure were synthesized and tested against A549 and Hela cancer cells. Based on the structure-based drug design strategy and docking results, incorporation of aliphatic heterocycles into pyrimidine ring improved the activity and selectivity of designed inhibitors by occupying the empty volume of protein. The un-substituted indole ring containing compounds <ce:bold>67a-c</ce:bold> (<ce:cross-ref id="crosref0900" refid="fig12">Fig. 12</ce:cross-ref>
                           <ce:float-anchor refid="fig12"/></ce:float-anchor>) showed excellent inhibitory activities against double mutant EGFR kinase (EGFR<ce:sup loc="post">T790M/L858R</ce:sup>) (IC<ce:inf loc="post">50s</ce:inf> = 35, 31 and 16 nM, respectively) and great selectivity toward EGFR<ce:sup loc="post">WT</ce:sup> kinase. In addition, the mentioned compounds especially sulfoxide containing derivative <ce:bold>67c</ce:bold> exhibited potent anti-proliferating activity with IC<ce:inf loc="post">50</ce:inf> values of 0.057, 0.104 and 0.9 μM, respectively against A549, Hela and H1975 cancer cells [<ce:cross-ref id="crosref0905" refid="bib96">96</ce:cross-ref>]. Novel series of thiopyran-pyrimidine derivatives were evaluated as novel olmutinib derivative against A549, H1975, Hela and MCF7 cancer cells. Based on the docking results, the structure of olmutinib was modified by replacement of thiophene-pyrimidine with more bulky thiopyran-pyrimidine core structure. Also, methoxyaniline was introduced to the C-2 of thiopyran-pyrimidine core, inspired by the methoxy group of phenylpiperazine on the side chain of WZ4002. Compound <ce:bold>68</ce:bold> (<ce:cross-ref id="crosref0910" refid="fig12">Fig. 12</ce:cross-ref>) showed the significant activity against A549 and H1975 in cellular assay with IC<ce:inf loc="post">50s</ce:inf> = 4.22 and 2.19 μM, respectively and strong inhibitory effect on EGFR kinases (92.7% inhibition at 1 μM concentration and IC<ce:inf loc="post">50</ce:inf> = 0.1 μM against mutant EGFR<ce:sup loc="post">T790M/L858R</ce:sup>). Further, compound <ce:bold>68</ce:bold> blocked the proliferation of H1975 cancer cells in G2/M phase and could effectively induced late apoptosis in concentration dependent manner [<ce:cross-ref id="crosref0915" refid="bib97">97</ce:cross-ref>].</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0105">Conclusion</ce:section-title>
                  <ce:para id="p0105" view="all">Targeted cancer therapy takes advantage of distinguishing between cancerous and normal cells, which leads to the significant improvements in effectiveness of cancer treatments and minimizing side effects. For this purpose, this approach inhibits specific enzyme or protein in cancer cells. The inhibition of EGFR kinase activity is considered as a promising approach for the treatment of cancers. Using EGFR TK inhibitory activity revolutionizes the cancer treatment with EGFR over-activation. Several synthetic anti-EGFR TK agents were evaluated in recent years, mostly exhibiting clinical efficacy in relevant models. In particular, pyrimidine-based molecules were successfully explored as promising EGFR TK inhibitors which have received enormous clinical success in treatment of cancer and subsequently, a number of FDA approved drugs such as osimertinib with pyrimidine core structure as common anticancer pharmacophore have been developed. However, the efficacy of these agents is often limited because of the quick emergence of drug resistance. Determination of drug resistance mechanism provided valuable clues for structural modification and rational design of small molecule as specific EGFR TK inhibitors in recent years. In this regard, additional information is needed to fully understand and overcome resistance problems for further development of novel small molecules as more efficient inhibitors. In recent years, a large number of pyrimidine containing derivatives were synthesized and evaluated which rationally designed to selectively target specific mutations in tyrosine kinase domain of EGFR. Most of these selective pyrimidine-based EGFR kinase inhibitors have shown promising biological results and progressed to clinical evaluations. This review provides an overview of targeting EGFR signaling pathways as an efficient approach in targeted cancer therapy. The latest advances in the design and the development of pyrimidine-containing compounds as selective EGFR TK inhibitors are investigated.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0110">Declaration of competing interest</ce:section-title>
               <ce:para id="p0110" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0115">Acknowledgement</ce:section-title>
               <ce:para id="p0115" view="all">This work was supported and funded by <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100012155" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Institute for Medical Research Development</ce:grant-sponsor>; Grant no. <ce:grant-number refid="gs1">962567</ce:grant-number>.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0120">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ayati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Emami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Asadipour</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Shafiee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Foroumadi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent applications of 1 , 3-thiazole core structure in the identi fi cation of new lead compounds and drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>97</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>699</sb:first-page>
                              <sb:last-page>718</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2015.04.015</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">A. Ayati, S. Emami, A. Asadipour, A. Shafiee, A. Foroumadi, Recent applications of 1 , 3-thiazole core structure in the identi fi cation of new lead compounds and drug discovery, Eur. J. Med. Chem. 97 (2015) 699-718. https://doi.org/10.1016/j.ejmech.2015.04.015.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Milik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Lasheen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.T.</ce:given-name>
                                 <ce:surname>Serya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.M.</ce:given-name>
                                 <ce:surname>Abouzid</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>How to train your inhibitor: design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>142</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>131</sb:first-page>
                              <sb:last-page>151</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2017.07.023</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">S.N. Milik, D.S. Lasheen, R.A.T. Serya, K.A.M. Abouzid, How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors, Eur. J. Med. Chem. 142 (2017) 131-151. https://doi.org/10.1016/j.ejmech.2017.07.023.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aghcheli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Toolabi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ayati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Moghimi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Firoozpour</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design , synthesis , and biological evaluation of as anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Chem. Res.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4</sb:first-page>
                              <sb:last-page>11</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/s00044-020-02616-2</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">A. Aghcheli, M. Toolabi, A. Ayati, S. Moghimi, L. Firoozpour, Design , synthesis , and biological evaluation of as anticancer agents, Med. Chem. Res. (2020) 4-11. https://doi.org/10.1007/s00044-020-02616-2.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Schrank</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chhabra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Iderzorig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Osude</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kuckovic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Id</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Puri</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Current molecular-targeted therapies in NSCLC and their mechanism of resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancers (Basel)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>224</sb:first-page>
                              <sb:last-page>241</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.3390/cancers10070224</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">Z. Schrank, G. Chhabra, L. Lin, T. Iderzorig, C. Osude, N. Khan, A. Kuckovic, S.S. Id, R.J. Miller, N. Puri, Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance, Cancers (Basel). 10 (2018) 224-241. https://doi.org/10.3390/cancers10070224.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeted therapy for cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Canc. Mol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>57</sb:first-page>
                              <sb:last-page>66</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">H. Wu, D. Chang, C. Huang, Targeted Therapy for Cancer, J. Cancer Mol. 2 (2006) 57-66.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ayati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Emami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Moghimi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Foroumadi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Thiazole in the targeted anticancer drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Future Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1929</sb:first-page>
                              <sb:last-page>1952</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.4155/fmc-2018-0416</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">A. Ayati, S. Emami, S. Moghimi, A. Foroumadi, Thiazole in the targeted anticancer drug discovery, Future Med. Chem. 11 (2019) 1929-1952. https://doi.org/10.4155/fmc-2018-0416.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Das</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>170</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>55</sb:first-page>
                              <sb:last-page>72</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2019.03.004</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">D. Das, J. Hong, Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry, Eur. J. Med. Chem. 170 (2019) 55-72. https://doi.org/10.1016/j.ejmech.2019.03.004.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kyriakopoulou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Kefali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Piperigkou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.K.</ce:given-name>
                                 <ce:surname>Karamanos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Signal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>99</sb:first-page>
                              <sb:last-page>109</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.cellsig.2018.07.010</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">K. Kyriakopoulou, E. Kefali, Z. Piperigkou, N.K. Karamanos, Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer, Cell. Signal. 51 (2018) 99-109. https://doi.org/10.1016/j.cellsig.2018.07.010.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Gore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Rajput</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A review on recent progress in multicomponent reactions of pyrimidine synthesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Investig. Today.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>148</sb:first-page>
                              <sb:last-page>152</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.dit.2013.05.010</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">R.P. Gore, A.P. Rajput, A review on recent progress in multicomponent reactions of pyrimidine synthesis, Drug Investig. Today. 5 (2013) 148-152. https://doi.org/10.1016/j.dit.2013.05.010.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Guan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Yongli</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ning1</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants Future</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Future Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>48</sb:first-page>
                              <sb:last-page>49</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/ja01486a066</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">H. Guan, Yongli Du, Y. Ning1, & X. Cao, A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants Future, Future Med. Chem. 31 (2017) 48-49. https://doi.org/10.1021/ja01486a066.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bhatia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Alam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Manaithiya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Alam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Alam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Imran</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>European Journal of Medicinal Chemistry Novel quinazoline-based EGFR kinase inhibitors: a review focussing on SAR and molecular docking studies ( 2015-2019 )</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>204</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>112640</sb:article-number>
                           <ce:doi>10.1016/j.ejmech.2020.112640</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">P. Bhatia, V. Sharma, O. Alam, A. Manaithiya, P. Alam, T. Alam, M. Imran, European Journal of Medicinal Chemistry Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies ( 2015-2019 ), Eur. J. Med. Chem. 204 (2020) 112640. https://doi.org/10.1016/j.ejmech.2020.112640.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hsieh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hsieh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chern</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acrylamide functional group incorporation improves drug-like Properties : an example with EGFR inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>22</sb:first-page>
                              <sb:last-page>26</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acsmedchemlett.8b00270</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">K. Wu, G.S. Chen, J. Liu, C. Hsieh, J. Chern, K. Wu, G.S. Chen, J. Liu, C. Hsieh, J. Chern, Acrylamide Functional Group Incorporation Improves Drug-Like Properties : An Example with EGFR Inhibitors, ACS Med. Chem. Lett. 10 (2019) 22-26. https://doi.org/10.1021/acsmedchemlett.8b00270.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Agustoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Suda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Christopher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ellison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Jr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Rozeboom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Brovsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.R.</ce:given-name>
                                 <ce:surname>Hirsch</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Treat Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>72</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>15</sb:first-page>
                              <sb:last-page>27</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ctrv.2018.08.002</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">F. Agustoni, K. Suda, H. Yu, S. Ren, J. Christopher, K. Ellison, C.C. Jr, L. Rozeboom, K. Brovsky, F.R. Hirsch, EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis, Cancer Treat. Rev. 72 (2019) 15-27. https://doi.org/10.1016/j.ctrv.2018.08.002.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Mountzios</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Making progress in epidermal growth factor receptor ( EGFR ) - mutant non-small cell lung cancer by surpassing resistance : third- generation EGFR tyrosine kinase inhibitors ( EGFR-TKIs )</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Transl. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>6</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.21037/atm.2017.10.04</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">G. Mountzios, Making progress in epidermal growth factor receptor ( EGFR ) - mutant non-small cell lung cancer by surpassing resistance : third- generation EGFR tyrosine kinase inhibitors ( EGFR-TKIs ), Ann. Transl. Med. 6 (2018) 1-6. https://doi.org/10.21037/atm.2017.10.04.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ciardiello</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Internistica</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Exp. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>158</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>9</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1111/j.1365-2249.2009.03992.x</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">F. Ciardiello, D.M. Internistica, Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy, Clin. Exp. Immunol. 158 (2009) 1-9. https://doi.org/10.1111/j.1365-2249.2009.03992.x.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ayati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Moghimi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Salarinejad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Safavi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Pouramiri</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A review on progression of epidermal growth factor receptor ( EGFR ) inhibitors as an efficient approach in cancer targeted therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>99</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>103811</sb:article-number>
                           <ce:doi>10.1016/j.bioorg.2020.103811</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">A. Ayati, S. Moghimi, S. Salarinejad, M. Safavi, B. Pouramiri, A review on progression of epidermal growth factor receptor ( EGFR ) inhibitors as an efficient approach in cancer targeted therapy, Bioorg. Chem. 99 (2020) 103811. https://doi.org/10.1016/j.bioorg.2020.103811.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Traxler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinases as targets in cancer therapy - successes and failures</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>215</sb:first-page>
                              <sb:last-page>234</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1517/14728222.7.2.215</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">P. Traxler, Tyrosine kinases as targets in cancer therapy - Successes and failures, Expert Opin. Ther. Targets. 7 (2003) 215-234. https://doi.org/10.1517/14728222.7.2.215.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ercan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Cortot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chirieac</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Iacob</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Padera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Engen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Eck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Jänne</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>462</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1070</sb:first-page>
                              <sb:last-page>1074</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nature08622.Novel</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">W. Zhou, D. Ercan, L. Chen, C. Yun, D. Li, A.B. Cortot, L. Chirieac, R.E. Iacob, R. Padera, J.R. Engen, K. Wong, M.J. Eck, N.S. Gray, P.A. Janne, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature. 462 (2009) 1070-1074. https://doi.org/10.1038/nature08622.Novel.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pawara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ansari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Surana</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>142</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>32</sb:first-page>
                              <sb:last-page>47</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2017.05.027</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">H. Patel, R. Pawara, A. Ansari, S. Surana, Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance, Eur. J. Med. Chem. 142 (2017) 32-47. https://doi.org/10.1016/j.ejmech.2017.05.027.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>385</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>51</sb:first-page>
                              <sb:last-page>54</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.canlet.2016.11.008</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">S. Wang, Y. Song, D. Liu, EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance, Cancer Lett. 385 (2017) 51-54. https://doi.org/10.1016/j.canlet.2016.11.008.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Grabe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lategahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Rauh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>C797S resistance: the undruggable EGFR mutation in non-small cell lung cancer?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>779</sb:first-page>
                              <sb:last-page>782</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acsmedchemlett.8b00314</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">T. Grabe, J. Lategahn, D. Rauh, C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?, ACS Med. Chem. Lett. 9 (2018) 779-782. https://doi.org/10.1021/acsmedchemlett.8b00314.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Gilbert</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent advances in irreversible kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharm. Pat. Anal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>375</sb:first-page>
                              <sb:last-page>386</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.4155/ppa.14.24</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">A.M. Gilbert, Recent advances in irreversible kinase inhibitors, Pharm. Pat. Anal. 3 (2014) 375-386. https://doi.org/10.4155/ppa.14.24.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Narasimhan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic potential of heterocyclic pyrimidine scaffolds</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Cent. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>29</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1186/s13065-018-0406-5</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">S. Kumar, B. Narasimhan, Therapeutic potential of heterocyclic pyrimidine scaffolds, Chem. Cent. J. 12 (2018) 1-29. https://doi.org/10.1186/s13065-018-0406-5.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Faraji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.O.</ce:given-name>
                                 <ce:surname>Bakhshaiesh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Hasanvand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Motahari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Nazeri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Boshagh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Firoozpour</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Mehrabi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Khalaj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Esmaeili</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Foroumadi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>214</sb:volume-nr>
                              </sb:series>
                              <sb:date>2021</sb:date>
                           </sb:issue>
                           <sb:article-number>113228</sb:article-number>
                           <ce:doi>10.1016/j.ejmech.2021.113228</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">A. Faraji, T. O. Bakhshaiesh, Z. Hasanvand, R. Motahari, E. Nazeri, M. A. Boshagh, L. Firoozpour, H. Mehrabi, A. Khalaj, R. Esmaeili, A. Foroumadi, Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis. Eur. J. Med. Chem. 214 (2021) 113228. https://doi.org/10.1016/j.ejmech.2021.113228.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dubrovskiy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Labenski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Overcomes T790M-mediated resistance in NSCLC</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1404</sb:first-page>
                              <sb:last-page>1415</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/2159-8290.CD-13-0314.Discovery</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">K. Lee, A. Dubrovskiy, M. Labenski, Z. Zhu, overcomes T790M-mediated resistance in NSCLC, Cancer Discov. 3 (2014) 1404-1415. https://doi.org/10.1158/2159-8290.CD-13-0314.Discovery.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4290</sb:first-page>
                              <sb:last-page>4300</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.7b01310</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">L. Chen, W. Fu, L. Zheng, Z. Liu, G. Liang, Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer, J. Med. Chem. 61 (2018) 4290-4300. https://doi.org/10.1021/acs.jmedchem.7b01310.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Girard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Futur. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2983</sb:first-page>
                              <sb:last-page>2997</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.2217/fon-2019-0400</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">N. Girard, Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates, Futur. Oncol. 15 (2019) 2983-2997. https://doi.org/10.2217/fon-2019-0400.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Smaill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting EGFR L858R/T790M and EGFR L858R/T790M/C797S resistance mutations in NSCLC : current developments in medicinal chemistry</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Med. Res. Rev.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>32</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/med.21488</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">X. Lu, J.B. Smaill, L. Yu, Targeting EGFR L858R/T790M and EGFR L858R/T790M/C797S resistance mutations in NSCLC : Current developments in medicinal chemistry, Med. Res. Rev. (2018) 1-32. https://doi.org/10.1002/med.21488.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>An</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.C.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>183</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>111709</sb:article-number>
                           <ce:doi>10.1016/j.ejmech.2019.111709</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">B. An, T. Pan, J. Hu, Y. Pang, L. Huang, A.S.C. Chan, X. Li, J. Yan, The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer, Eur. J. Med. Chem. 183 (2019) 111709. https://doi.org/10.1016/j.ejmech.2019.111709.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Mcaulay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Hoyt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Schimpl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Bodnarchuk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Barratt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bhavsar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Deery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.L.</ce:given-name>
                                 <ce:surname>Bernardes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Ward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Waring</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Kettle</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Alkynyl benzoxazines and dihydroquinazolines as cysteine targeting covalent warheads and their application in identification of selective irreversible kinase inhibitors alkynyl benzoxazines and dihydroquinazolines as cysteine targeting covalent warheads</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Am. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>142</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10358</sb:first-page>
                              <sb:last-page>10372</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jacs.9b13391</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">K. Mcaulay, E.A. Hoyt, M. Thomas, M. Schimpl, M.S. Bodnarchuk, H.J. Lewis, D. Barratt, D. Bhavsar, D.M. Robinson, M.J. Deery, G.J.L. Bernardes, R.A. Ward, M.J. Waring, J.G. Kettle, Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads, J. Am. Chem. Soc. 142 (2020) 10358-10372. https://doi.org/10.1021/jacs.9b13391.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Lan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>163</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>367</sb:first-page>
                              <sb:last-page>380</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2018.11.069</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">B. Zhao, Z. Xiao, J. Qi, R. Luo, Z. Lan, Y. Zhang, X. Hu, Q. Tang, P. Zheng, S. Xu, W. Zhu, Design, synthesis and biological evaluation of AZD9291 derivatives as selective and potent EGFRL858R/T790M inhibitors, Eur. J. Med. Chem. 163 (2019) 367-380. https://doi.org/10.1016/j.ejmech.2018.11.069.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Rao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and evaluation of osimertinib derivatives as potent EGFR inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4553</sb:first-page>
                              <sb:last-page>4559</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmc.2017.06.004</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">H. Gao, Z. Yang, X. Yang, Y. Rao, Synthesis and evaluation of osimertinib derivatives as potent EGFR inhibitors, Bioorg. Med. Chem. 25 (2017) 4553-4559. https://doi.org/10.1016/j.bmc.2017.06.004.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design , synthesis and evaluation of the osimertinib analogue ( C-005 ) as potent EGFR inhibitor against NSCLC</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6135</sb:first-page>
                              <sb:last-page>6145</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmc.2018.10.018</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">P. Zhou, G. Chen, M. Gao, J. Wu, Design , synthesis and evaluation of the osimertinib analogue ( C-005 ) as potent EGFR inhibitor against NSCLC, Bioorg. Med. Chem. 26 (2018) 6135-6145. https://doi.org/10.1016/j.bmc.2018.10.018.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>135</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12</sb:first-page>
                              <sb:last-page>23</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2017.04.036</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">H. Zhang, W. Wu, C. Feng, Z. Liu, E. Bai, X. Wang, M. Lei, H. Cheng, H. Feng, J. Shi, J. Wang, Z. Zhang, T. Jin, S. Chen, S. Hu, Y. Zhu, Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants, Eur. J. Med. Chem. 135 (2017) 12-23. https://doi.org/10.1016/j.ejmech.2017.04.036.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Basu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Richters</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Rauh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design and synthesis of covalent- reversible inhibitors to overcome drug resistance in EGFR</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2767</sb:first-page>
                              <sb:last-page>2780</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmc.2015.04.038</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">D. Basu, A. Richters, D. Rauh, Structure-based design and synthesis of covalent- reversible inhibitors to overcome drug resistance in EGFR, Bioorg. Med. Chem. 23 (2015) 2767-2780. https://doi.org/10.1016/j.bmc.2015.04.038.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Qu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2673</sb:first-page>
                              <sb:last-page>2680</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmc.2016.04.032</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">Q. Xiao, R. Qu, D. Gao, Q. Yan, L. Tong, W. Zhang, J. Ding, H. Xie, Y. Li, Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors, Bioorganic Med. Chem. 24 (2016) 2673-2680. https://doi.org/10.1016/j.bmc.2016.04.032.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Romu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Lei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Korlipara</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design , synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4832</sb:first-page>
                              <sb:last-page>4837</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmcl.2017.09.048</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">A.A. Romu, Z. Lei, B. Zhou, Z. Chen, V. Korlipara, Design , synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors, Bioorg. Med. Chem. Lett. 27 (2017) 4832-4837. https://doi.org/10.1016/j.bmcl.2017.09.048.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.Y.V.N.V.</ce:given-name>
                                 <ce:surname>Stolpovskayaa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Kruzhilina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Zorinaa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Kh S.</ce:given-name>
                                 <ce:surname>Shikhalieva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.V.</ce:given-name>
                                 <ce:surname>Ledenevaa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Koshelevaa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis of substituted aminopyrimidines as novel promising tyrosine kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Russ. J. Org. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1322</sb:first-page>
                              <sb:last-page>1328</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1134/S1070428019090094</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">D.Y.V. N. V. Stolpovskayaa, A. A. Kruzhilina, A. V. Zorinaa, Kh. S. Shikhalieva, I. V. Ledenevaa, E. A. Koshelevaa, Synthesis of Substituted Aminopyrimidines as Novel Promising Tyrosine Kinase Inhibitors, Russ. J. Org. Chem. 55 (2019) 1322-1328. https://doi.org/10.1134/S1070428019090094.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Silakari</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular dynamics guided development of indole based dual inhibitors of EGFR ( T790M ) and c-MET</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>79</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>163</sb:first-page>
                              <sb:last-page>170</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bioorg.2018.04.001</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">P.K. Singh, O. Silakari, Molecular dynamics guided development of indole based dual inhibitors of EGFR ( T790M ) and c-MET, Bioorg. Chem. 79 (2018) 163-170. https://doi.org/10.1016/j.bioorg.2018.04.001.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Qu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Patterson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Smaill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>2, 4- diarylamino-pyrimidines as kinase inhibitors Co-targeting IGF1R and EGFRL858R/T790M</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4277</sb:first-page>
                              <sb:last-page>4281</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmcl.2015.07.089</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">S. Chan, K. Han, R. Qu, L. Tong, Y. Li, Z. Zhang, H. Cheng, X. Lu, A. Patterson, J. Smaill, X. Ren, J. Ding, H. Xie, K. Ding, 2, 4- Diarylamino-pyrimidines as Kinase Inhibitors Co-targeting IGF1R and EGFRL858R/T790M, Bioorg. Med. Chem. Lett. 25 (2015) 4277-4281. https://doi.org/10.1016/j.bmcl.2015.07.089.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ansari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pawara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Ansari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jadhav</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of novel 2 , 4-disubstituted aminopyrimidines : reversible non-covalent T790M EGFR inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Recept. Signal Transduct.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>393</sb:first-page>
                              <sb:last-page>412</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/10799893.2018.1557207</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">H. Patel, A. Ansari, R. Pawara, I. Ansari, H. Jadhav, Design and synthesis of novel 2 , 4-disubstituted aminopyrimidines : reversible non-covalent T790M EGFR inhibitors, J. Recept. Signal Transduct. 38 (2019) 393-412. https://doi.org/10.1080/10799893.2018.1557207.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Qu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>152</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>298</sb:first-page>
                              <sb:last-page>306</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2018.04.052</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">Q. Yan, Y. Chen, B. Tang, Q. Xiao, R. Qu, L. Tong, J. Liu, J. Ding, Y. Chen, N. Ding, W. Tan, H. Xie, Y. Li, Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation, Eur. J. Med. Chem. 152 (2018) 298-306. https://doi.org/10.1016/j.ejmech.2018.04.052.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Fusheng Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Lv</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of N-aryl-N ’-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1257</sb:first-page>
                              <sb:last-page>1261</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmcl.2017.12.009</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">J.L. Fusheng Zhou, L. Zhang, Y. Jin, W. Liu, P. Cheng, X. He, J. Xie, S. Shen, J. Lei, H. Ji, Y. Hu, Y. Liu, Y. Cui, Q. Lv, Discovery of N-aryl-N ’-pyrimidin-4-yl ureas as Irreversible L858R/T790M Mutant Selective Epidermal Growth Factor Receptor Inhibitors, Bioorg. Med. Chem. Lett. 28 (2018) 1257-1261. https://doi.org/10.1016/j.bmcl.2017.12.009.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives ( AzDPPYs ) as potent T790M mutant form of epidermal growth factor receptor inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5505</sb:first-page>
                              <sb:last-page>5512</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmc.2016.09.001</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">Z. Song, Y. Jin, Y. Ge, C. Wang, J. Zhang, Z. Tang, J. Peng, K. Liu, Y. Li, X. Ma, Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives ( AzDPPYs ) as potent T790M mutant form of epidermal growth factor receptor inhibitors, Bioorg. Med. Chem. 24 (2016) 5505-5512. https://doi.org/10.1016/j.bmc.2016.09.001.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation in non-small cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol. Drug Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>92</sb:volume-nr>
                              </sb:series>
                              <sb:issue-nr>6</sb:issue-nr>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1988</sb:first-page>
                              <sb:last-page>1997</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1111/cbdd.13370</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">Y. Yia, L. Wang, D. Zhao, S. Huang, C. Wang, Z. Liu, H. Sun, K. Liu, X. Ma, Y. Li, ,Structural Optimization of Diphenylpyrimidine Scaffold as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation in Non-small Cell Lung Cancer, Chem. Biol. Drug. Des. 92(6) (2018) 1988-1997. https://doi.org/10.1111/cbdd.13370.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Meng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Shu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>133</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>329</sb:first-page>
                              <sb:last-page>339</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2017.03.083</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">Z. Song, S. Huang, H. Yu, Y. Jiang, C. Wang, Q. Meng, X. Shu, H. Sun, K. Liu, Y. Li, X. Ma, Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC), Eur. J. Med. Chem. 133 (2017) 329-339. https://doi.org/10.1016/j.ejmech.2017.03.083.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>94</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>103408</sb:article-number>
                           <ce:doi>10.1016/j.bioorg.2019.103408</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">M. Ai, C. Wang, Z. Tang, K. Liu, X. Sun, T. Ma, Y. Li, X. Ma, L. Li, L. Chen, Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines, Bioorg. Chem. 94 (2020) 103408. https://doi.org/10.1016/j.bioorg.2019.103408.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.L.Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of N-(5-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGF</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>139</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>674</sb:first-page>
                              <sb:last-page>697</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2017.08.035</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">J.L. Y. Chen, J. Wu, A. Wang, Z. Qi, T. Jiang, C. Chen, F. Zou, C. Hu, W. Wang, H. Wu, Z. Hu, W. Wang, B. Wang, L. Wang, T. Ren, S. Zhang, Q. Liu, J. Liu, Discovery of N-(5-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGF, Eur. J. Med. Chem. 139 (2017) 674-697. https://doi.org/10.1016/j.ejmech.2017.08.035.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and SAR study of 2-aminopyrimidines with diverse Michael addition acceptors for chemically tuning the potency against EGFR L858R/T790M</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>115680</sb:article-number>
                           <ce:doi>10.1016/j.bmc.2020.115680</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">J. Shao, S. Liu, X. Liu, Y. Pan, W. Chen, Design, synthesis and SAR study of 2-aminopyrimidines with diverse Michael addition acceptors for chemically tuning the potency against EGFR L858R/T790M, Bioorg. Med. Chem. 28 (2020) 115680. https://doi.org/10.1016/j.bmc.2020.115680.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.L.</ce:given-name>
                                 <ce:surname>Lingfeng Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Qu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Qiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>140</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>510</sb:first-page>
                              <sb:last-page>527</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2017.08.061</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">G.L. Lingfeng Chen, W. Fu, C. Feng, R. Qu, L. Tong, L. Zheng, B. Fang, Y. Qiu, J. Hu, Y. Cai, J. Feng, H. Xie, J. Ding, Z. Liu, Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC, Eur. J. Med. Chem. 140 (2017) 510-527. https://doi.org/10.1016/j.ejmech.2017.08.061.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors mutations inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Enzym. Inhib. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1233</sb:first-page>
                              <sb:last-page>1246</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/14756366.2019.1634704</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">L. Ye, T. Zhao, W. Du, A. Li, W. Gao, J. Li, L. Wang, Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors mutations inhibitors, J. Enzyme Inhib. Med. Chem. 34 (2019) 1233-1246. https://doi.org/10.1080/14756366.2019.1634704.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lv</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>157</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1300</sb:first-page>
                              <sb:last-page>1325</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2018.08.031</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">Y. Zhang, H. Lv, L. Luo, Y. Xu, Y. Pan, Y. Wang, H. Lin, J. Xiong, P. Guo, J. Zhang, X. Li, F. Ye, Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer, Eur. J. Med. Chem. 157 (2018) 1300-1325. https://doi.org/10.1016/j.ejmech.2018.08.031.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>187</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>111943</sb:article-number>
                           <ce:doi>10.1016/j.ejmech.2019.111943</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">Z. Xie, K. Wu, Y. Wang, Y. Pan, B. Chen, D. Cheng, S. Pan, T. Guo, X. Du, L. Fang, X. Wang, F. Ye, Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC, Eur. J. Med. Chem. 187 (2020) 111943. https://doi.org/10.1016/j.ejmech.2019.111943.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.H.A.</ce:given-name>
                                 <ce:surname>Khaled</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Abdellatifa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Belalb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>El-Saadib</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.H.</ce:given-name>
                                 <ce:surname>Eman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Saidb</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design , synthesis , molecular docking and antiproliferative activity of some novel benzothiazole derivatives targeting EGFR/HER2 and TS</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>103976</sb:article-number>
                           <ce:doi>10.1016/j.bioorg.2020.103976</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">N.H.A. Khaled, R.A. Abdellatifa, A. Belalb, M. T. El-Saadib, L.R.H. Eman, G. Saidb, Design , synthesis , molecular docking and antiproliferative activity of some novel benzothiazole derivatives targeting EGFR/HER2 and TS, Bioorg. Chem. 101 (2020) 103976. https://doi.org/10.1016/j.bioorg.2020.103976.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Elkamhawy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Paik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.H.E.</ce:given-name>
                                 <ce:surname>Hassan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Joo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Hit discovery of 4-amino- N - ( 4- ( 3- ( trifluoromethyl ) phenoxy ) pyrimidin- 5-yl ) benzamide : a novel EGFR inhibitor from a designed small library</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>75</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>393</sb:first-page>
                              <sb:last-page>405</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bioorg.2017.10.009</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">A. Elkamhawy, S. Paik, A.H.E. Hassan, Y. Sup, E. Joo, Hit discovery of 4-amino- N - ( 4- ( 3- ( trifluoromethyl ) phenoxy ) pyrimidin- 5-yl ) benzamide : A novel EGFR inhibitor from a designed small library, Bioorg. Chem. 75 (2017) 393-405. https://doi.org/10.1016/j.bioorg.2017.10.009.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Elkamhawy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.H.E.</ce:given-name>
                                 <ce:surname>Hassan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Paik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>EGFR inhibitors from cancer to inflammation: discovery of 4-fluoro- N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl) benzamide as a novel anti- inflammatory EGFR inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>86</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>112</sb:first-page>
                              <sb:last-page>118</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bioorg.2019.01.017</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">A. Elkamhawy, A.H.E. Hassan, S. Paik, Y. Sup, H. Lee, EGFR inhibitors from cancer to inflammation: Discovery of 4-fluoro- N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl) benzamide as a novel anti- inflammatory EGFR inhibitor, Bioorg. Chem. 86 (2019) 112-118. https://doi.org/10.1016/j.bioorg.2019.01.017.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.B.</ce:given-name>
                                 <ce:surname>Hengmiao Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Nair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Almaden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bailey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.F.</ce:given-name>
                                 <ce:surname>Doug</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4- yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4- methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2005</sb:first-page>
                              <sb:last-page>2024</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.5b01633</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">S.B. Hengmiao Cheng, S. K. Nair, B. W. Murray, C. Almaden, S. Bailey, J.L.F. Doug, Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4- yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4- methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants, J. Med. Chem. 59 (2016) 2005-2024. https://doi.org/10.1021/acs.jmedchem.5b01633.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kurup</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Mcallister</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Liskova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Mistry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Stanford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Slawska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Keller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hoellein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and biological activity of N - amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Enzym. Inhib. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>74</sb:first-page>
                              <sb:last-page>84</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/14756366.2017.1376666</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">S. Kurup, B. Mcallister, P. Liskova, T. Mistry, D. Stanford, J. Slawska, U. Keller, A. Hoellein, Design, synthesis and biological activity of N - amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase, J. Enzyme Inhib. Med. Chem. 33 (2018) 74-84. https://doi.org/10.1080/14756366.2017.1376666.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Fischer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Krüger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Najjar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Totzke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schächtele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Sippl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ritter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hilgeroth</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2708</sb:first-page>
                              <sb:last-page>2712</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmcl.2017.04.053</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">T. Fischer, T. Kruger, A. Najjar, F. Totzke, C. Schachtele, W. Sippl, C. Ritter, A. Hilgeroth, Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors, Bioorg. Med. Chem. Lett. 27 (2017) 2708-2712. https://doi.org/10.1016/j.bmcl.2017.04.053.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Reiersølmoen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Aarhus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Eckelt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Gabestad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sundby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.H.</ce:given-name>
                                 <ce:surname>Hoff</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent and selective EGFR inhibitors based on 5-aryl-7<ce:italic>H</ce:italic>-pyrrolopyrimidin-4-amines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>88</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>102918</sb:article-number>
                           <ce:doi>10.1016/j.bioorg.2019.102918</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0325">A.C. Reiersoelmoen, T. Aarhus, S. Eckelt, K. Gabestad, E. Sundby, B.H. Hoff, Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines, Bioorg. Chem. 88 (2019) 102918. https://doi.org/10.1016/j.bioorg.2019.102918.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Engel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Becker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lategahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Keul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ketzer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Mühlenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kollipara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schultz-fademrecht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Zahedi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Rauh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Insight into the inhibition of drug-resistant mutants of the receptor tyrosine kinase EGFR</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Angew. Chem. Int.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>5</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/anie.201605011</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">J. Engel, C. Becker, J. Lategahn, M. Keul, J. Ketzer, T. Muhlenberg, L. Kollipara, C. Schultz-fademrecht, R.P. Zahedi, S. Bauer, D. Rauh, Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR, Angew. Chem. Int. 55 (2016) 1-5. https://doi.org/10.1002/anie.201605011.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Gaber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.H.</ce:given-name>
                                 <ce:surname>Bayoumi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>El-morsy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.F.</ce:given-name>
                                 <ce:surname>Sherbiny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.M.</ce:given-name>
                                 <ce:surname>Mehany</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.H.</ce:given-name>
                                 <ce:surname>Eissa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design , synthesis and anticancer evaluation of 1 H -pyrazolo [ 3 , 4- d ] pyrimidine derivatives as potent EGFR WT and EGFR T790M inhibitors and apoptosis inducers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>80</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>375</sb:first-page>
                              <sb:last-page>395</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bioorg.2018.06.017</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">A.A. Gaber, A.H. Bayoumi, A.M. El-morsy, F.F. Sherbiny, A.B.M. Mehany, I.H. Eissa, Design , synthesis and anticancer evaluation of 1 H -pyrazolo [ 3 , 4- d ] pyrimidine derivatives as potent EGFR WT and EGFR T790M inhibitors and apoptosis inducers, Bioorg. Chem. 80 (2018) 375-395. https://doi.org/10.1016/j.bioorg.2018.06.017.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Abdelgawad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Bakr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.A.</ce:given-name>
                                 <ce:surname>Alkhoja</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.R.</ce:given-name>
                                 <ce:surname>Mohamed</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>88</sb:first-page>
                              <sb:last-page>96</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bioorg.2016.03.011</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0340">M.A. Abdelgawad, R.B. Bakr, O.A. Alkhoja, W.R. Mohamed, Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors, Bioorg. Chem. 66 (2016) 88-96. https://doi.org/10.1016/j.bioorg.2016.03.011.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Maher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Kassab</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Zaher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Mahmoud</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis , anticancer activity , dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity , effects on cell cycle profile and caspase-3- mediated apoptosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Enzym. Inhib. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>532</sb:first-page>
                              <sb:last-page>546</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/14756366.2018.1564046</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0345">M. Maher, A.E. Kassab, A.F. Zaher, Z. Mahmoud, synthesis , anticancer activity , dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity , effects on cell cycle profile and caspase-3- mediated apoptosis, J. Enzyme Inhib. Med. Chem. 34 (2019) 532-546. https://doi.org/10.1080/14756366.2018.1564046.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.M.</ce:given-name>
                                 <ce:surname>Saleh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>El-gazzar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Aly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Othman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel anticancer fused pyrazole derivatives as EGFR and VEGFR-2 dual TK inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>12</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.3389/fchem.2019.00917</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0350">N.M. Saleh, M.G. El-gazzar, H.M. Aly, R.A. Othman, Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors, Front. Chem. 7 (2020) 1-12. https://doi.org/10.3389/fchem.2019.00917.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Jia</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and antitumor evaluation of novel derivatives as potential EGFR inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arch. Pharm.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>11</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/ardp.201800110</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0355">D. Zhang, X. Jia, Synthesis and antitumor evaluation of novel derivatives as potential EGFR inhibitors, Arch Pharm. (2018) 1-11. https://doi.org/10.1002/ardp.201800110.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Jing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Miao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lei</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery and optimization of tetrahydropyrido [ 4 , 3- d ] pyrimidine derivatives as novel ATX and EGFR dual inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1784</sb:first-page>
                              <sb:last-page>1796</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmc.2018.02.023</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0360">T. Jing, X. Miao, F. Jiang, M. Guo, L. Xing, J. Zhang, D. Zuo, H. Lei, Discovery and optimization of tetrahydropyrido [ 4 , 3- d ] pyrimidine derivatives as novel ATX and EGFR dual inhibitors, Bioorg. Med. Chem. 26 (2018) 1784-1796. https://doi.org/10.1016/j.bmc.2018.02.023.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>[68]</ce:label>
                     <sb:reference id="sref68">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A structure-guided optimization of pyrido [ 2 , 3- d ] pyrimidin-7-ones as selective inhibitors of EGFR L858R/T790M mutant with improved pharmacokinetic properties</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>126</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1107</sb:first-page>
                              <sb:last-page>1117</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2016.12.006</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0365">L. Yu, M. Huang, T. Xu, L. Tong, X. Yan, Z. Zhang, A structure-guided optimization of pyrido [ 2 , 3- d ] pyrimidin-7-ones as selective inhibitors of EGFR L858R/T790M mutant with improved pharmacokinetic properties, Eur. J. Med. Chem. 126 (2017) 1107-1117. https://doi.org/10.1016/j.ejmech.2016.12.006.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib69">
                     <ce:label>[69]</ce:label>
                     <sb:reference id="sref69">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of selective degraders of EGFR L858R/T790M mutant</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>192</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>112199</sb:first-page>
                              <sb:last-page>112213</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2020.112199</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0370">X. Zhang, F. Xu, L. Tong, T. Zhang, H. Xie, X. Lu, X. Ren, K. Ding, Design and synthesis of selective degraders of EGFR L858R/T790M mutant, Eur. J. Med. Chem. 192 (2020) 112199-112213. https://doi.org/10.1016/j.ejmech.2020.112199.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib70">
                     <ce:label>[70]</ce:label>
                     <sb:reference id="sref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Xin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido [ 3 , 4- d ] pyrimidine sca ff old</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3619</sb:first-page>
                              <sb:last-page>3633</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmc.2018.05.039</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0375">H. Zhang, J. Wang, H. Zhao, X. Yang, H. Lei, M. Xin, Y. Cao, Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido [ 3 , 4- d ] pyrimidine sca ff old, Bioorg. Med. Chem. 26 (2018) 3619-3633. https://doi.org/10.1016/j.bmc.2018.05.039.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib71">
                     <ce:label>[71]</ce:label>
                     <sb:reference id="sref71">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of 5-methylpyrimidopyridone derivatives as new wild-type sparing inhibitors of the epidermal growth factor receptor triple mutant (EGFRL858R/T790M/C797S)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7302</sb:first-page>
                              <sb:last-page>7308</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.9b00576</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0380">J. Shen, T. Zhang, S. Zhu, M. Sun, L. Tong, M. Lai, R. Zhang, W. Xu, R. Wu, J. Ding, C. Yun, H. Xie, X. Lu, K. Ding, Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S), J. Med. Chem. 62 (2019) 7302-7308. https://doi.org/10.1021/acs.jmedchem.9b00576.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib72">
                     <ce:label>[72]</ce:label>
                     <sb:reference id="sref72">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.M.</ce:given-name>
                                 <ce:surname>Khalifa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Al-omar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Alkahtani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.H.</ce:given-name>
                                 <ce:surname>Bakheit</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinase inhibitors of novel pyridopyrimidinone Candidates : synthesis and in vitro anticancer properties</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem.</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>2635219</sb:article-number>
                           <ce:doi>10.1155/2019/2635219</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0385">N.M. Khalifa, M.A. Al-omar, H.M. Alkahtani, A.H. Bakheit, Kinase Inhibitors of Novel Pyridopyrimidinone Candidates : Synthesis and In Vitro Anticancer Properties, J. Chem. (2019) 2635219. https://doi.org/10.1155/2019/2635219.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib73">
                     <ce:label>[73]</ce:label>
                     <sb:reference id="sref73">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.S.A.</ce:given-name>
                                 <ce:surname>Elzahabi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.S.</ce:given-name>
                                 <ce:surname>Nossier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.M.</ce:given-name>
                                 <ce:surname>Khalifa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Enzym. Inhib. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>546</sb:first-page>
                              <sb:last-page>557</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/14756366.2018.1437729</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0390">H. S. A. Elzahabi, E. S. Nossier, N. M. Khalifa, Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold, J. Enzyme Inhib. Med. Chem. 33 (2018) 546-557. https://doi.org/10.1080/14756366.2018.1437729.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib74">
                     <ce:label>[74]</ce:label>
                     <sb:reference id="sref74">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>El Sayed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.R.</ce:given-name>
                                 <ce:surname>Hussein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.M.</ce:given-name>
                                 <ce:surname>Elebiary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Hassan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Elmessery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Elsheakh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nayel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Abdel-aziz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d] pyrimidines ligand: synthesis , biological screening and molecular modeling studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>78</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>312</sb:first-page>
                              <sb:last-page>323</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bioorg.2018.03.009</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0395">M.T. El Sayed, H.A.R. Hussein, N.M. Elebiary, G.S. Hassan, S.M. Elmessery, A.R. Elsheakh, M. Nayel, H.A. Abdel-aziz, Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d] pyrimidines ligand: Synthesis , biological screening and molecular modeling studies, Bioorg. Chem. 78 (2018) 312-323. https://doi.org/10.1016/j.bioorg.2018.03.009.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib75">
                     <ce:label>[75]</ce:label>
                     <sb:reference id="sref75">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Xin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFRTKIs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>148</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>221</sb:first-page>
                              <sb:last-page>237</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2018.02.051</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0400">H. Zhang, J. Wang, Y. Shen, H. Wang, W. Duan, H. Zhao, Y. Hei, M. Xin, Y. Cao, S. Zhang, Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFRTKIs, Eur. J. Med. Chem. 148 (2018) 221-237. https://doi.org/10.1016/j.ejmech.2018.02.051.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib76">
                     <ce:label>[76]</ce:label>
                     <sb:reference id="sref76">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.-Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.-X.</ce:given-name>
                                 <ce:surname>Xi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Xin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.-X.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of potent epidermal growth factor receptor ( EGFR ) degraders by proteolysis targeting chimera ( PROTAC )</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>189</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>112061</sb:first-page>
                              <sb:last-page>112076</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2020.112061</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0405">H. Zhang, H-Y. Zhao, X-X. Xi, Y-J. Liu, M. Xin, S. Mao, J-J. Zhang, A-X. Lu, Discovery of potent epidermal growth factor receptor ( EGFR ) degraders by proteolysis targeting chimera ( PROTAC ), Eur. J. Med. Chem. 189 (2020) 112061-112076. https://doi.org/10.1016/j.ejmech.2020.112061.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib77">
                     <ce:label>[77]</ce:label>
                     <sb:reference id="sref77">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lyu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Qu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5609</sb:first-page>
                              <sb:last-page>5622</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.8b00346</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0410">Y. Hao, J. Lyu, R. Qu, Y. Tong, D. Sun, F. Feng, L. Tong, T. Yang, Z. Zhao, L. Zhu, J. Ding, Y. Xu, H. Xie, H. Li, Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation, J. Med. Chem. 61 (2018) 5609-5622. https://doi.org/10.1021/acs.jmedchem.8b00346.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib78">
                     <ce:label>[78]</ce:label>
                     <sb:reference id="sref78">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Xun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Su</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of JND3229 as a new EGFR C797S mutant inhibitor with in vivo mono-drug efficacy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1123</sb:first-page>
                              <sb:last-page>1127</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acsmedchemlett.8b00373</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0415">X. Lu, T. Zhang, S. Zhu, Q. Xun, L. Tong, X. Hu, Y. Li, S. Chan, Y. Su, Y. Sun, Y. Chen, J. Ding, CH. Yun, H. Xie, K. Ding, Discovery of JND3229 as a New EGFR C797S Mutant Inhibitor with In Vivo Mono-drug Efficacy, ACS Med. Chem. Lett. 9 (2018) 1123-1127. https://doi.org/10.1021/acsmedchemlett.8b00373.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib79">
                     <ce:label>[79]</ce:label>
                     <sb:reference id="sref79">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Xun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant Xianglong</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chin. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1281</sb:first-page>
                              <sb:last-page>1287</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.cclet.2019.09.044</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0420">X. Hu, Q. Xun, T. Zhang, S. Zhu, Q. Li, L. Tong, M. Lai, T. Huang, C. Yun, H. Xie, K. Ding, X. Lu, 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant Xianglong, Chinese Chem. Lett. 31 (2019) 1281-1287. https://doi.org/10.1016/j.cclet.2019.09.044.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib80">
                     <ce:label>[80]</ce:label>
                     <sb:reference id="sref80">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Kaspersen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nervik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nørsett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sundby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hoff</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>119</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>278</sb:first-page>
                              <sb:last-page>299</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2016.04.054</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0425">J. Han, S.J. Kaspersen, S. Nervik, K. Noersett, E. Sundby, H. Hoff, Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors, Eur. J. Med. Chem. 119 (2016) 278-299. https://doi.org/10.1016/j.ejmech.2016.04.054.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib81">
                     <ce:label>[81]</ce:label>
                     <sb:reference id="sref81">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hossam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Lasheen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.M.</ce:given-name>
                                 <ce:surname>Ismail</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Esmat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.A.N.B.</ce:given-name>
                                 <ce:surname>Singab</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.M.</ce:given-name>
                                 <ce:surname>Abouzid</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>144</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>330</sb:first-page>
                              <sb:last-page>348</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2017.12.022</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0430">M. Hossam, D. S. Lasheen, N. S.M. Ismail, A. Esmat, A. M. A.N.B. Singab, K.A.M. Abouzid, Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity, Eur. J. Med. Chem. 144 (2018) 330-348. https://doi.org/10.1016/j.ejmech.2017.12.022.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib82">
                     <ce:label>[82]</ce:label>
                     <sb:reference id="sref82">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Coumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Shiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Leou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Chittimalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hsieh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4980</sb:first-page>
                              <sb:last-page>4988</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm1000198</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0435">M.S. Coumar, C. Chu, C. Lin, H. Shiao, Y. Ho, R. Reddy, W. Lin, C. Chen, Y. Peng, J. Leou, T. Lien, C. Huang, M. Fang, S. Wu, J. Wu, S.K. Chittimalla, J. Song, S. Wu, C. Liao, Y. Chao, H. Hsieh, Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor, J. Med. Chem. 53 (2010) 4980-4988. https://doi.org/10.1021/jm1000198.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib83">
                     <ce:label>[83]</ce:label>
                     <sb:reference id="sref83">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Shiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Lyu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hsieh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinase inhibitor design by targeting the asp-phe-gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3889</sb:first-page>
                              <sb:last-page>3903</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm400072p</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0440">Y. Peng, H. Shiao, C. Tu, P. Liu, J.T. Hsu, S. Wang, W. Lin, H. Sun, Y. Chao, P. Lyu, H. Hsieh, Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors, J. Med. Chem. 56 (2013) 3889-3903. https://doi.org/10.1021/jm400072p.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib84">
                     <ce:label>[84]</ce:label>
                     <sb:reference id="sref84">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.-Y.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-H.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.-Y.</ce:given-name>
                                 <ce:surname>Ke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Shiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Kuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yeh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of a furanopyrimidine-based epidermal growth factor receptor inhibitor (DBPR112) as a clinical candidate for the treatment of non-small cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10108</sb:first-page>
                              <sb:last-page>10123</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.9b00722</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0445">S-Y. Lin, Y.C. Hsu, Y-H. Peng, Y-Y. Ke, W. Lin, H. Sun, H. Shiao, F. Kuo, P. Chen, T. Lien, C. Chen, C. Chu, S. Wang, K. Yeh, C. Chen, T. Hsu, S. Wu, T. Yeh, Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer, J. Med. Chem. 62 (2019) 10108-10123. https://doi.org/10.1021/acs.jmedchem.9b00722.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib85">
                     <ce:label>[85]</ce:label>
                     <sb:reference id="sref85">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Hanan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Baumgardner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Bryan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Eigenbrot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Gu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>La</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Malek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.E.</ce:given-name>
                                 <ce:surname>Purkey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Schaefer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Schmidt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sideris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Yen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Heffron</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>534</sb:first-page>
                              <sb:last-page>539</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmcl.2015.11.078</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0450">E.J. Hanan, M. Baumgardner, M.C. Bryan, Y. Chen, C. Eigenbrot, P. Fan, X. Gu, H. La, S. Malek, H.E. Purkey, G. Schaefer, S. Schmidt, S. Sideris, I. Yen, C. Yu, T.P. Heffron, 4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase, Bioorg. Med. Chem. Lett. 26 (2016) 534-539. https://doi.org/10.1016/j.bmcl.2015.11.078.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib86">
                     <ce:label>[86]</ce:label>
                     <sb:reference id="sref86">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Devambatla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Choudhary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ihnat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hamel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Mooberry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gangjee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design , synthesis and preclinical evaluation of 5-methyl- N4-aryl-furo[2,3-d] pyrimidines as single agents with combination chemotherapy potential</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3085</sb:first-page>
                              <sb:last-page>3093</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmcl.2018.07.039</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0455">R. Kumar, V. Devambatla, S. Choudhary, M. Ihnat, E. Hamel, S.L. Mooberry, A. Gangjee, Design , synthesis and preclinical evaluation of 5-methyl- N4-aryl-furo[2,3-d] pyrimidines as single agents with combination chemotherapy potential, Bioorg. Med. Chem. Lett. 28 (2018) 3085-3093. https://doi.org/10.1016/j.bmcl.2018.07.039.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib87">
                     <ce:label>[87]</ce:label>
                     <sb:reference id="sref87">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bugge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Formo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Jurisch-yaksi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Ullestad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Martine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sundby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Helge</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Extended structure e activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>107</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>255</sb:first-page>
                              <sb:last-page>274</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2015.11.012</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0460">S. Bugge, A. Formo, N. Jurisch-yaksi, I. Ullestad, E. Martine, E. Sundby, B. Helge, Extended structure e activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties, Eur. J. Med. Chem. 107 (2016) 255-274. https://doi.org/10.1016/j.ejmech.2015.11.012.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib88">
                     <ce:label>[88]</ce:label>
                     <sb:reference id="sref88">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Milik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Abdel-Aziz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Lasheen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.T.</ce:given-name>
                                 <ce:surname>Serya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Minucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.M.</ce:given-name>
                                 <ce:surname>Abouzid</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>155</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>316</sb:first-page>
                              <sb:last-page>336</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.ejmech.2018.06.011</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0465">S. N. Milik, A. K. Abdel-Aziz, D. S. Lasheen, R. A.T. Serya, S. Minucci, K.A.M. Abouzid, Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors, Eur. J. Med. Chem. 155 (2018) 316-336. https://doi.org/10.1016/j.ejmech.2018.06.011.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib89">
                     <ce:label>[89]</ce:label>
                     <sb:reference id="sref89">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Romagnoli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Prencipe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Oliva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Baraldi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Baraldi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Schia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Chayah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Salvador</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Lopez-cara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Brancale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ferla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hamel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ronca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bortolozzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Mariotto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Mattiuzzo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Viola</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and biological evaluation of 6-substituted thieno[3,2-d]pyrimidine analogues as dual epidermal growth factor receptor kinase and microtubule inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1274</sb:first-page>
                              <sb:last-page>1290</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.8b01391</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0470">R. Romagnoli, F. Prencipe, P. Oliva, S. Baraldi, P.G. Baraldi, S. Schia, M. Chayah, M.K. Salvador, L.C. Lopez-cara, A. Brancale, S. Ferla, E. Hamel, R. Ronca, R. Bortolozzi, E. Mariotto, E. Mattiuzzo, G. Viola, Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors, J. Med. Chem. 62 (2019) 1274-1290. https://doi.org/10.1021/acs.jmedchem.8b01391.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib90">
                     <ce:label>[90]</ce:label>
                     <sb:reference id="sref90">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Toolabi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Moghimi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.O.</ce:given-name>
                                 <ce:surname>Bakhshaiesh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Salarinejad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aghcheli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Hasanvand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Nazeri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Khalaj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Esmaeili</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Foroumadi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>6-Cinnamoyl-4-arylaminothienopyrimidines as highly potent cytotoxic agents: design, synthesis and structure-activity relationship studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>185</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>111786</sb:article-number>
                           <ce:doi>10.1016/j.ejmech.2019.111786</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0475">M. Toolabi, S. Moghimi, T.O. Bakhshaiesh, S. Salarinejad, A. Aghcheli, Z. Hasanvand, E. Nazeri, A. Khalaj, R. Esmaeili, A. Foroumadi, 6-Cinnamoyl-4-arylaminothienopyrimidines as highly potent cytotoxic agents: Design, synthesis and structure-activity relationship studies, Eur. J. Med. Chem. 185 (2019) 111786. https://doi.org/10.1016/j.ejmech.2019.111786.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib91">
                     <ce:label>[91]</ce:label>
                     <sb:reference id="sref91">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Abd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Hadi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Lasheen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Hassan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.M.</ce:given-name>
                                 <ce:surname>Abouzid</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based compounds as dual EGFR/HER-2 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Arch. Pharm.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>349</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>21</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/ardp.201600197</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0480">S.R. Abd, E. Hadi, D.S. Lasheen, M.A. Hassan, K.A.M. Abouzid, Design and Synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors, ARCH PHARM. 349 (2016) 1-21. https://doi.org/10.1002/ardp.201600197.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib92">
                     <ce:label>[92]</ce:label>
                     <sb:reference id="sref92">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Elmetwally</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.F.</ce:given-name>
                                 <ce:surname>Saied</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.H.</ce:given-name>
                                 <ce:surname>Eissa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.B.</ce:given-name>
                                 <ce:surname>Elkaeed</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>88</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>102944</sb:article-number>
                           <ce:doi>10.1016/j.bioorg.2019.102944</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0485">S.A. Elmetwally, K.F. Saied, I.H. Eissa, E.B. Elkaeed, Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers, Bioorg. Chem. 88 (2019) 102944. https://doi.org/10.1016/j.bioorg.2019.102944.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib93">
                     <ce:label>[93]</ce:label>
                     <sb:reference id="sref93">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.E.-S.</ce:given-name>
                                 <ce:surname>Mghwary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Gedawy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Kamal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Abuel-Maaty</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors : design , synthesis , anticancer activity and effect on cell cycle profile</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Enzym. Inhib. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>838</sb:first-page>
                              <sb:last-page>852</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/14756366.2019.1593160</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0490">A.E-S. Mghwary, E.M. Gedawy, A.M. Kamal, S.M. Abuel-Maaty, Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors : design , synthesis , anticancer activity and effect on cell cycle profile, J. Enzyme Inhib. Med. Chem. 34 (2019) 838-852. https://doi.org/10.1080/14756366.2019.1593160.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib94">
                     <ce:label>[94]</ce:label>
                     <sb:reference id="sref94">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>203</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>112511</sb:article-number>
                           <ce:doi>10.1016/j.ejmech.2020.112511</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0495">Z. Xiao, Z. Zhou, C. Chu, Q. Zhang, L. Zhou, Z. Yang, X. Li, L. Yu, P. Zheng, S. Xu, W. Zhu, Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations, Eur. J. Med. Chem. 203 (2020) 112511. https://doi.org/10.1016/j.ejmech.2020.112511.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib95">
                     <ce:label>[95]</ce:label>
                     <sb:reference id="sref95">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Qiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of new thieno [ 3 , 2- d ] pyrimidine derivatives targeting EGFR L858R/T790M NSCLCs by the conformation constrained strategy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>199</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>112388</sb:article-number>
                           <ce:doi>10.1016/j.ejmech.2020.112388</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0500">Y. Chen, L. Yang, H. Qiao, Z. Cheng, J. Xie, W. Zhou, X. Huang, Y. Jiang, B. Yu, W. Zhao, Discovery of new thieno [ 3 , 2- d ] pyrimidine derivatives targeting EGFR L858R/T790M NSCLCs by the conformation constrained strategy, Eur. J. Med. Chem. 199 (2020) 112388. https://doi.org/10.1016/j.ejmech.2020.112388.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib96">
                     <ce:label>[96]</ce:label>
                     <sb:reference id="sref96">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Lan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and 3D-QSAR analysis of novel thiopyranopyrimidine derivatives as potential antitumor agents inhibiting A549 and Hela cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>185</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>111809</sb:article-number>
                           <ce:doi>10.1016/j.ejmech.2019.111809</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0505">B. Zhao, C. Zhao, X. Hu, S. Xu, Z. Lan, Y. Guo, Z. Yang, W. Zhu, P. Zheng, Design, synthesis and 3D-QSAR analysis of novel thiopyranopyrimidine derivatives as potential antitumor agents inhibiting A549 and Hela cancer cells, Eur. J. Med. Chem. 185 (2019) 111809. https://doi.org/10.1016/j.ejmech.2019.111809.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib97">
                     <ce:label>[97]</ce:label>
                     <sb:reference id="sref97">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>115669</sb:article-number>
                           <ce:doi>10.1016/j.bmc.2020.115669</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0510">Z. Xiao, C. Chu, L. Zhou, Z. Zhou, Q. Zhang, F. Yang, Z. Yang, P. Zheng, S. Xu, W. Zhu, Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors, Bioorg. Med. Chem. 28 (2020) 115669. https://doi.org/10.1016/j.bmc.2020.115669.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>